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Multiple sclerosis (MS) is a chronic autoimmune-mediated demyelinating disease 
that affects more than 2.3 million people worldwide, especially young adults. The 
etiology is unknown, and effective treatments are unavailable. Viral infection(s) 
has been postulated to play a critical role in the initiation and progression of 
MS. My study utilizes a mouse model called Theiler’s murine encephalomyelitis 
virus-induced demyelinating disease (TMEV-IDD) to better understand human 
MS. In TMEV-IDD, microglia, a resident macrophage in the central nervous 
system (CNS), are persistently infected with TMEV. As a result, the infected 
microglia produce an innate immune response that has been shown to contribute 
to bystander damage, bystander activation, and inflammation in the 
CNS, ultimately leading to demyelination. My central hypothesis is that exosomes 
secreted by microglia during TMEV infection may play an important role in 
sustaining persistence of virus and inflammation in the CNS, contributing to the 
development of demyelinating disease. We found that exosomes secreted 
by microglia during the acute phase (2 days post infection, dpi) and chronic 
phase (starting at 63dpi) of TMEV infection have altered surface markers and 
importantly, contain viral RNA/genome. We discovered that these exosomes are 
able to transfer viral RNA to uninfected CNS and infiltrating bystander cells to 
activate an innate immune response including expression of type I IFNs, pro-
inflammatory cytokines, chemokines, and effector molecules. This activation was 
prominently triggered by the recognition viral RNA in exosomes by innate 
immune receptors. Naïve mice injected with exosomes secreted by microglia 
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during TMEV infection showed microglia activation, neuroinflammation, and 
demyelination. In summary, these findings shed light on the role of exosomes in 
maintaining viral persistence and sustaining inflammation which are crucial in the 
development of virus-induced demyelinating disease in mice, and possibly 
human MS. The knowledge from this work may allow for identification of new 
therapeutic targets or disease-modifying strategies to treat demyelinating disease 
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Background and literature review  
1. MULTIPLE SCLEROSIS (MS)   
MS is a chronic, inflammatory demyelinating disease of the central 
nervous system (CNS). In MS, the myelin sheet surrounding the axon is 
impaired, which results in a breakdown of communication between neurons and 
progressive and permanent nerve deterioration. The incidence of MS is highest 
in people ages 20 to 40, with the incidence among women compared to men 
being significantly higher at a 3:1 ratio respectively1, 2. MS in the pediatric 
population is rare and occurs in 1 every 100,000 cases 3. The diagnosis of MS is 
difficult because it is primarily a clinical diagnosis that requires an objective 
demonstration of dissemination of CNS in both space and time. Clinical 
manifestations are dependent on the location and stage of lesion/damage with 
symptoms such as tremors, focal or multifocal neurologic deficits, facial 
paresthesia, diplopia, dysarthria, bladder dysfunction, ataxia, or spastic paralysis 
4.  Imaging with magnetic resonance imaging (MRI) can be helpful and is the 
preferred imaging test to identify whether patients have CNS plaques or lesions 
at different regions in both white and grey matter of the brain and spinal cord. 
Diagnosis of MS is thus based upon clinical findings alone or a combination of 
clinical and magnetic resonance imaging (MRI) findings. MS is a complex 
disease with heterogeneous phenotypes that are categorized into four main 
types5. The most common (~87%) form of MS is relapse-remitting (RRMS), 
which is described by episodes of reversible neurological attacks. Once the 
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attacks become more frequent and protuberant, the patients can develop 
secondary progressive MS (SPMS). On the other hand, primary progressive MS 
(PPMS) (~10%) is the most severe phenotype with irreversible progressive 
clinical symptoms. PPMS lesions tend to locate in the spinal cord rather than the 
brain and are associated with more serious symptoms such as ataxia and 
paralysis5.  
There is no cure for MS and existing treatment is focused on reducing the 
severity of attacks or relapses, expediting recovery, or slowing disease 
progression.  Current therapies employ temporary immunomodulation and/or 
immunosuppression, which need to be administered regularly and have adverse 
side effects that increase the patient’s risk for infection and malignancy6. Immune 
reconstitution therapy using embryonic or mesenchymal stem cells has shown 
promising long-lasting outcomes in some patients but carries significant mortality 
due to its high adverse effect profile7. More research is needed to understand 
the pathophysiology of MS so that new therapeutics can be developed to 
ultimately improve patient outcomes   
2. MS PATHOGENESIS    
The cause of MS is unknown, and the combination of environmental 
agents, genetic predisposition, and immunological components have been 
suggested to contribute to the disease pathogenesis5, 8, 9. Among those, viral 
infections contracted during childhood (the first 15 years of life) that act as 
potential triggers have been extensively studied 9-11. In recent years, ubiquitous 
viruses belonging to the herpesvirus family such as Epstein-Barr virus (EBV) and 
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human herpesvirus 6 (HHV 6) have gained significant interest. Studies have 
shown that high titer of antibodies against EBV and increased circulating HHV-6 
proteins are consistently detected in body fluids of MS patients during relapse 
and progression 12, 13.    
Traditionally, MS has been classified as an autoimmune disease 
associated with myelin-specific T cells and B cells. However, recent studies have 
suggested that the role of these adaptive immune cells is likely the result of 
another upstream process14, 15. Our hypothesis is that there is a viral etiology that 
causes CNS-resident inflammatory immune cells, mainly microglia, to activate 
and induce infiltration of peripheral lymphocytes, including myelin-specific T cell 
and B cells, which result in the death of myelin-producing oligodendrocytes and 
neuron apoptosis. Our work focuses on further exploring a viral etiology as a 
cause for MS.   
3. MICROGLIA   
Microglia Development and Function   
The CNS was once thought to be the immune-privileged organ until the 
discovery of the lymphatic drainage system16.  The CNS equips itself with the 
specialized innate immune cell called microglia to rapidly respond to pathogenic 
infections and injury, minimize unnecessary crosstalk with peripheral cells, thus 
maintaining homeostasis and tissue vigilance 17. Microglia make up 
approximately 15% of CNS cells and have the ability to self-regenerate. These 
cells are commonly known as the CNS-resident macrophages due to their shared 
immunological functions, phenotypes, and morphology. Since microglia and 
 4 
monocytes/macrophages express similar surface markers (CD45, CD11b, Iba1, 
CD68, and CX3CR1, and others), distinguishing one from the other has been a 
great challenge for researchers. Nonetheless, microglia originate from the yolk 
sac and migrate the CNS at early development (embryonic day 9.5, E9.5) and 
reside strictly in the parenchyma18, 19. On the other hand, monocytes/ 
macrophages are derived from post-natal bone marrow cells and populate 
peripherally including choroid plexus, perivascular space, and meninges18. Under 
normal conditions, microglia stay quiescent and stationary, using their elongated 
and fine processes to patrol the extracellular space and maintain homeostasis by 
performing tasks such as CNS debris/plaque scavenging, neuronal repair, and 
synaptic pruning.   
As innate immune cells, microglia also serve as the first line of defense in 
the CNS against pathogens. Upon viral infections, microglia become activated to 
secrete type I interferons (INFs, IFNα, and IFNβ), chemokines(CCL2, CCL3, and 
CCL5), pro-inflammatory cytokines (interleukin (IL)- 1β, IL-6, IL-12, and TNFα) as 
well as anti-inflammatory cytokines (IL-10 and arginase) to recruit and activate 
other immune cells at the infection site to combat the virus and remove apoptotic 
bodies20, 21. On the surface, microglia express co-stimulatory molecules CD80, 
CD86 and CD40 and both major histocompatibility complex (MHC) class I and II, 
and thus are able to present foreign antigens to CD4+ and CD8+ T cells to 
orchestrate T cell-mediated and direct killing of infected cells21. The phenotypic 
plasticity of the microglia enables them to perform both inflammatory and anti-
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inflammatory functions, thus, their role in disease pathogenesis is often 
controversial.   
Microglia in MS    
Microglial activation and inflammation are the gold standard hallmarks of 
MS pathology. Clinical studies found clusters of activated microglia not only in 
the active/demyelinating lesions but also in the intact white matter of MS patients, 
which were termed “pre-active lesions”22. These pre-active lesions are void of 
infiltrating lymphocytes and often progress into active lesions23. Activated 
microglia stained positive for myelin degradation products such as myelin basic 
protein (MBP) and proteolipid protein (PLP) are detected consistently throughout 
early demyelinating and post demyelinating lesions23. Transmembrane protein 
119, TMEM119 has been proposed to be the microglia specific marker present in 
the active lesion24. About 43% of phagocytes are TMEM119 positive and ionized 
calcium-binding adaptor molecule 1 (Iba1) positive, and these double-positive 
microglia are present at the border of mixed active/inactive lesions, indicating 
that microglia may play a key role in MS progression25.  
In both human MS and murine demyelinating disease models, microglia 
have been shown to upregulate their expression of pro-inflammatory cytokines 
such as IL-1β, IL-18, IL-6, and chemokines CCL2 and CCL5, to recruit and 
activate T cells, thereby contributing to CNS inflammation and 
neurodegeneration. Reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) secreted from microglia can act on oligodendrocytes and neurons 
to induce impaired remyelination and axonal damage, respectively. Overall, 
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these clinical studies agree with animal experimental studies, suggesting that 
microglia are indeed involved in the initiation, progression, and even 
remyelination of MS lesions. However, the trigger(s) remain undetermined. 
Targeting microglia could potentially be a new therapeutic option for MS.    
4. THEILER’S MURINE ENCEPHALOMYELITIS VIRUS-INDUCED 
DEMYELINATING DISEASE (TMEV-IDD)   
 TMEV is a positive sense, single-stranded (ss) which belongs to 
the Piconaviridae family. Infection of TMEV (BeAn 8386 strain) in susceptible 
mouse strain (Swiss Jim Lambert, SJL) can lead to viral persistence in 
microglia and development of chronic progressive demyelinating disease 
associated with proteolipid peptide (PLP)139-151 -specific CD4+Th1 type T 
cells, approximately 55 days post-infection (dpi)21, 26-28.  Clinical symptoms in 
mice can be observed around 35 dpi, which include spastic paralysis in the hind 
limbs and gaiting difficulty29, 30. The demyelination seen in the TMEV-
IDD appears to not be due to the cytolytic effect in glial cells but rather immune-
mediated, which closely recapitulates the immunopathology seen in human 
MS.  Hence, TMEV-IDD is an appropriate mouse model for studying the virologic 
and mechanisms involved in human chronic progressive MS.   
Both the innate and adaptive immune responses play inevitable roles in 
driving the development and progression of TMEV-IDD through mechanisms 
including bystander activation, bystander damage, and epitope spreading31. 
Interestingly, a comprehensive transcriptional study demonstrated that although 
the expression of the adaptive immune response was upregulated early (30dpi) 
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in TMEV-IDD, the innate immune genes were more prominent at the late chronic 
stage (165dpi) of TMEV-IDD32. This seemingly counterintuitive observation 
suggests that more research is needed in investigating the activity of the innate 
immune cells in sustaining neuroinflammation during the chronic stage.  
Role of the CNS innate immune response to TMEV infection and 
demyelination.    
The innate immune response becomes activated by the recognition of 
pathogen-associated molecular patterns (PAMPs) through innate immune 
receptors, predominantly Toll-like receptors (TLRs) which are expressed in most 
cells. TLR7 and TLR8 were shown to recognize viral ssRNA, while TLR3, 
intracellular melanoma differentiation-associated protein 5 (MDA5) and retinoic 
acid-inducible gene 1 (RIG-I) recognize viral dsRNA33-37. TLR7 signals through a 
common adaptor protein myeloid differentiation primary response gene 88 
(MyD88) resulting in downstream activation of the NF-kB family of transcription 
factors38.  Meanwhile, TLR3 signals through TIR-domain-containing adaptor-
inducing interferon β (TRIF) adaptor which leads to the cascade of interferon 
regulatory factor (IRF)-3 and IRF-739. MDA5 and RIG-I also involve activation of 
IRF-340. All of these engagements result in transcriptional expression of 
cytokines, chemokines, and effector molecules contributing to an inflammatory 
milieu.   
Inflammation is the hallmark of demyelinating diseases including MS. The 
susceptibility to demyelinating disease development in mice is greatly dependent 
on the magnitude of the innate immune response following TMEV infection41. 
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Shortly after intracranial inoculation of TMEV, type I IFNs (IFNβ and IFNα) are 
immediately produced by the CNS innate immune cells. Type I IFNS are 
prominent antiviral mediators such as promoting blastogenesis and proliferation 
of natural killer (NK) cells independent of IL-2 pathway, as well as enhancing 
their cytolytic effect on infected cells 42. Type I IFNs also mediate the adaptive 
immune response by driving CD4+ T cells toward the Th1 type response and 
induce IFN𝛾 secretion by T cells to promote expression of MHC class I and II on 
antigen-presenting cells (APCs), macrophage activation, and B cell class 
switching (IgG2a)43-45. Studies from our lab have shown that administration of 
IFNβ, not IFNα, shortly post-infection reduced the development and slowed the 
progression of TMEV-IDD and was associated with a decrease in pro-
inflammatory cytokines, mononuclear cells infiltration, and myelin-specific CD4+ T 
cells response41. In contrast, the administration of an antibody against IFNβ 
correlates with an increase in disease severity of the demyelinating disease41. 
Role of the adaptive immune response in TMEV infection and 
demyelination.   
Persistent infection due to inefficient viral clearance is another central 
condition in demyelinating disease development. After one week of post-TMEV 
infection, peripheral immune cells are recruited into the CNS as the blood-brain 
barrier (BBB) integrity is compromised by the cytokines and chemokines 
released by innate immune cells. Viral clearance clearly showed the importance 
of disease initiation as CD8+T cell depleted-resistant mice or β2-microglobulin- 
deficient mice develop chronic infection and demyelination after TMEV 
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challenge30, 46. In addition, an insufficient immune response from virus-specific 
CD8+T cells is linked to the H-2K locus on the MHC class I genes in susceptible 
mouse strands47. However, CD8+T cells appeared to minimally contribute to the 
progression of TMEV-demyelinating disease as the deletion of CD8+T cells did 
not rescue susceptible mice from disease development48.   
In TMEV-IDD, there are TMEV-specific CD4+T cells and myelin-specific 
CD4+T cells, and their involvements are significant in disease development. MHC 
class II-restricted, TMEV-specific CD4+T cells play a role in the initiation of the 
disease because the rise of these cells happens as early as 5 dpi and their peak 
(14dpi) coincides with the clinical disease onset49, 50. The immune response from 
viral-specific CD4+ T cells may have a bystander damage effect on surrounding 
myelinated neurons30. Induced toleration of CD4+T cells with TMEV antigens 
leads to reduced severity of disease and secretion of Th1-type pro-inflammatory 
cytokines51. On the other hand, myelin-specific CD4+T cells are found to be 
involved in the chronic demyelinating phase of TMEV-IDD as these cells do not 
arise until 50-55dpi49. Autoreactive CD4+T against PLP139-151 was consistently 
isolated from the CNS of mice during TMEV-IDD. Not only that, reactivity to 
myelin epitopes of CD4+T cells progresses in order (PLP56-70, myelin 
oligodendrocyte glycoprotein (MOG)92-106, PLP178-191, myelin basic protein 
(MBP)84-104), introducing the concept of epitope spreading. Most importantly, 
peripheral tolerance of PLP and MBP using recombinant fusion protein halts the 
disease progression.   
Role of microglia in TMEV-IDD development and progression   
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Microglia have been implicated in the pathogenesis of mouse TMEV-IDD 
and human MS due to their pro-inflammatory nature. They are the first cells to 
arrive at the infection site and express innate immune receptors which enable 
them to rapidly respond to pathogens invading the CNS. Microglia are 
persistently infected with TMEV and become activated through the innate 
immune receptors to express cytokines, chemokines, and effector molecules20. 
We have previously shown that TMEV infection of microglia leads to rapid 
expression of IFNα and IFNβ41. We have also shown that microglia infected with 
TMEV become activated to express pro-inflammatory cytokines, IL-1 β, IL-6, IL-
12, TNFα, chemokines, CCL2, CCL3, CCL5, and effector molecules like 
inducible nitric oxide (iNOS)41. TMEV- infected microglia also become activated 
antigen-presenting cells that can present viral antigens and myelin antigens to 
CD4+ T cells21.  Hence, we are compelled to understand more about how 
microglia are involved in maintaining viral persistence, neuroinflammation, and 
demyelination following TMEV infection.  
5. EXOSOMES   
Exosome biogenesis  
Almost all eukaryotic cells constitutively release extracellular vesicles (EVs) 
that can be taken up by other cells, thus mediating intercellular communication. 
The exosome is a subset of EVs, classified by its nanoscopic size (30-160 
nanometers, nm) and distinct biogenesis. These nanovesicles are generated by 
the clathrin-mediated inward budding of the endosomal membrane to form 
multivesicular bodies (MVBs). Before being released into the extracellular space, 
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they are called intraluminal vesicles (ILVs). Once the ILVs are released by the 
fusion of MVBs with the cell membrane, they become exosomes. The exosome 
membranes resemble the lipid bilayer membrane containing cell-specific makers 
as well as exosome-specific markers such as tetraspanin (CD63, CD81, and 
CD9) and syndecans52, 53. Exosomes contain proteins, lipids, and nucleic acids, 
including mRNA, microRNA, and DNA54. The composition of the exosomal  
membrane allows them to securely transfer various materials across stringent 
structures such as the BBB and prevent the degradation from surrounding 
RNAse and proteases55. Studies have suggested that the exosomal content 
sorting and delivery destination are rather programmed and not arbitrary as 
previously thought. The sorting of exosomal content and packaging require 
proteins of the endosomal sorting complex (ESCRT), ALG2 interacting protein X 
(ALIX), and tumor susceptibility genes (TSG101)56, 57. The cellular markers 
expressed on exosomes may steer exosomes to target specific cells and the 
uptake is dependent on the cell type 58, 59. Nonetheless, this area of exosome 
research needs more investigation  
Roles of exosomes in diseases  
 Recent studies have revealed the important role of exosomes in the 
pathogenesis of neurodegenerative diseases via the transfer of miRNAs, 
pathogenic, and misfolded proteins from rafts to recipient cells55, 60. Some efforts 
were delegated on studying the role of exosomes in MS, mainly by using 
experimental autoimmune encephalitis (EAE), a mouse model of human relapse-
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remitting MS. Thus, how exosomes are involved in the chronic progressive MS 
remains a substantial gap in knowledge.   
 More recently, exosomes represent a novel pathway in pathogenesis and 
immune evasion of viruses. Exosomes isolated from the sera of chronically 
infected hepatitis C virus (HCV) patients showed to contain replication-competent 
viral RNA61. Further, exosome-packaged HCV could induce the phenotype and 
cytokine profile switch in recipient macrophage62. Another study demonstrated 
that exosomes secreted by human immunodeficient virus (HIV)1–infected cells 
contained trans activator of transcription (Tat) protein promote bystander 
neurotoxicity seen in with HIV-associated neurocognitive diseases63. Once 
packaged inside the exosomes, viruses and their components would be 
protected from antibodies, thus possibly enhancing viral transmission and 
persistence.  
Another topic of interest is pathogenic roles of extracellular EVs, 
specifically exosomes, in cancer metastasis. Tumor-derived exosomes have 
shown to contribute to the formation of a premetastatic niche and determine 
specific organotrophic metastasis via exosomal integrins. Exosomal integrins 
mediate the interaction of tumor-derived exosomes and the resident cells, and 
uptake of tumor-derived exosomes leads to activation of proto-oncogene 
tyrosine-protein kinase Src (Src) phosphorylation and pro-inflammatory S100 
gene expression64.  Tumor-derived exosomes can deliver critical miRNAs, 
lncRNAs, and proteins that contribute to angiogenesis and acquisition of tumor-
associated cell phenotype65. Moreover, exosomes prepare the surrounding 
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microenvironment to be amenable for tumor colonization. Epithelial ovarian 
cancer cells have been shown to transfer miRNA that inhibit the activity of STAT3 
and cause an imbalance of Treg and Th17 cells that lead to an immune-
suppressive microenvironment66. Thus, we attempted to explore whether EVs 





















Exosomes secreted by microglia during virus infection in the 
central nervous system activate an inflammatory response in 
bystander cells and promote CNS inflammation 
Authors: Nhungoc Luong and Julie K. Olson 
*This work was submitted for publication in the Journal of Virology. 
BACKGROUND 
 Theiler’s murine encephalomyelitis virus (TMEV) is a natural mouse 
pathogen that can establish a persistent virus infection in the central nervous 
system (CNS).  TMEV is a picornavirus which has a single positive- stranded 
RNA genome and has no envelope.  TMEV infection of susceptible mice, such as 
SJL mice, establishes a persistent infection in the microglia/macrophage in the 
brain and spinal cord21, 26. The persistent infection leads to the development of a 
chronic, progressive demyelinating disease beginning with clinical disease 
around day 35 to 40 days post infection11, 30.  TMEV-induced demyelinating 
disease has been shown to be associated with an inflammatory immune 
response in the CNS and development of autoimmune CD4+ T cell response 
directed against myelin antigen, proteolipid protein, PLP139-15127, 28. We have 
previously shown that the innate immune response to virus infection influences 
the development and progression of demyelinating disease41, 67.  TMEV- induced 
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demyelinating disease has several immunological and pathological similarities to 
multiple sclerosis (MS) in humans68, 69.    
 Microglia are the resident immune cells of the CNS that originate from the 
yolk sac during development.  Microglia express innate immune receptors which 
enable them to rapidly respond to pathogens invading the CNS20.  Microglia 
become activated through the innate immune receptors to express cytokines, 
chemokines, and effector molecules.  We have previously shown that TMEV 
infection of microglia leads to a rapid expression of type I interferons, IFNα and 
IFNβ21.  We have also shown that microglia infected with TMEV become 
activated to express pro-inflammatory cytokines, IL1β, IL-6, IL-12, TNFα, 
chemokines, CCL2, CCL3, CCL5, and effector molecules, inducible nitric oxide 
(iNOS)20, 21.  TMEV-infected microglia also become activated antigen presenting 
cells that can present viral antigens and myelin antigens to CD4+ T cells21.    
 Exosomes are derived from microvesicular bodies (80-120nm) within the 
cell and are then released from the cell.  Exosomes secreted from one cell can 
fuse with target cells releasing the components of the exosome into the target 
cell, thus exosomes provide a means of communication between cells.  
Exosomes contain proteins, lipids, and nucleic acids, including mRNA, 
microRNA, and DNA54.  The exosome membranes resemble the lipid bilayer 
membrane containing exosome-specific markers such as tetraspanin (CD63, 
CD81) and syndecans52, 53.  The exosomal structure allows them to securely 
transfer various materials across the blood-brain barrier and prevent the 
degradation from surrounding RNAse and proteases55.  Recent studies have 
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revealed the important role of exosomes in the pathogenesis of 
neurodegenerative diseases via the transfer of miRNAs, pathogenic, and 
misfolded proteins from rafts to recipient cells55, 60.  More recently, exosomes 
have been isolated from the sera of chronically infected hepatitis C virus (HCV) 
patients and shown to contain replication-competent viral RNA 61. Further studies 
showed that exosome-packaged HCV could induce phenotype and cytokine 
profile switch in recipient macrophages62.  
 Exosomes represent a novel pathway for communication between cells, 
thus exosomes secreted by microglia may play an important role in 
communication between cells in the CNS.  Microglia have been shown to be 
infected during TMEV infection, thus we wanted to determine whether TMEV- 
infected microglia secrete exosomes which may contribute to persistent viral 
infection and inflammation in the CNS.  Our studies determined that exosomes 
secreted from microglia during TMEV infection do not contain TMEV viral 
particles but do contain the viral RNA genome which can be transferred to 
uninfected CNS resident cells such as microglia, astrocytes, and neurons.  More 
importantly, these exosomes activated bystander CNS cells to express type I 
interferons and pro-inflammatory cytokines and chemokines through innate 
immune receptor recognition of the viral RNA.  Further, exosomes secreted by 
microglia in the brain during TMEV infection did not contain viral particles but 
contained viral RNA which could be transferred to naïve mice activating an 
inflammatory immune response in the recipient mice.  The results from these 
studies suggest a new pathway via exosomes by which viral RNA can be 
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transferred during persistent infection in the CNS independent of viral particles 
and by which neuroinflammation can be maintained during persistent virus 
infection in the CNS.  
RESULTS 
Microglia infected with TMEV secrete exosomes that contain viral RNA 
Microglia secrete exosomes under normal conditions, therefore, we 
wanted to determine whether exosomes secreted by microglia during TMEV 
infection have altered contents.   Microglia were infected with TMEV, and 
exosomes were isolated after 24 hours. The isolation of exosomes was 
determined based on expression of exosome specific proteins such as CD63, 
shown by flow cytometry (Figure 1 A, F), and CD9, CD81, TSG101, and Rab 
proteins, as determined by mass spectrometry (Table I).  The exosomes also 
lacked the expression of Grp94, calnexin, cytochrome C, histones, and 
argonaute/RISC complex which are associated with other types of extracellular 
vesicles.  The exosomes were further examined by TEM and Nanosight to 
determine purity and size with average size about 120nm (Figure 1K and Figure 
2A).  These analyses confirmed the isolation and definition of exosomes for 
publication as determined by the International Society for Extracellular Vesicles70.  
Furthermore, the exosomes isolated from TMEV- infected microglia do not 
contain viral particles based on TEM analysis which showed no viral particles 
inside the exosomes or associated with exosomes, viral plaque assays of 
exosome isolations which resulted in no plaques on BHK cells, mass 
spectrometric analysis of isolated exosomes which detected no viral proteins 
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present in exosomes, and Nanosight particle size of exosomes which showed no 
particles smaller than 60 nm (TMEV is 30-40nm) (Figure 1K, Figure 2A, B, C, 
and Table 1).  Next, we wanted to determine whether exosomes secreted from 
microglia contain surface proteins similar to microglia.  Exosomes isolated from 
both uninfected and infected microglia have CD11b on the surface (Figure 1B 
and G).  Exosomes from uninfected microglia have low levels of co-stimulatory 
molecules, CD80 and CD86, and do not have MHC class II (Figure 1 C, D, E, H, 
I, J).  Interestingly, exosomes from TMEV-infected microglia have higher levels of 
co-stimulatory molecules and have MHC class II compared to exosomes from 
uninfected microglia. 
Exosomes have been shown to contain RNA, therefore, we wanted to 
determine whether exosomes from TMEV-infected microglia contain viral RNA.  
The exosomes were isolated from TMEV-infected microglia and examined for 
viral RNA.  First, primers for a short piece at the beginning of the viral genome 
were used to generate a 200bp product which showed that viral RNA was 
present in the exosomes from TMEV-infected exosomes similar to microglia 
infected with TMEV (Figure 3A).  Since TMEV is a small positive- strand RNA 
virus, we wanted to determine whether the entire genome was present in the 
exosomes.  Primers were used to generate a long piece which includes the 
coding region of the viral genome.  Exosomes from TMEV-infected microglia 
contained the viral genome similar to TMEV-infected microglia (Figure 3A). 
Since the exosomes secreted from TMEV-infected microglia contain viral 
RNA and exosomes can be taken up by other cells, we wanted to determine 
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whether exosomes from TMEV-infected microglia can be taken up by uninfected 
microglia, bystander cells, thus transferring viral RNA.  First, exosomes from 
TMEV-infected microglia were isolated and labeled with green fluorescence 
before being place on uninfected microglia to determine whether the exosomes 
were taken up by the uninfected microglia (Figure 3B).  Next, the RNA inside the 
exosomes isolated from TMEV-infected microglia was labeled with fluorescence 
dye before exosomes were placed on bystander microglia (Figure 3C, D). The 
RNA from the TMEV-infected exosomes can be observed inside the cytoplasm of 
the bystander microglia and over time can be observed spreading around in the 
cytoplasm of the bystander microglia.  To further determine whether the viral 
RNA was transferred to uninfected bystander microglia, the exosomes from the 
TMEV-infected microglia were added to the bystander microglia, and after 24 
hours, the bystander microglia were lysed and analyzed for viral RNA inside the 
cells.  The bystander microglia contained viral RNA, although at lower levels than 
microglia directly infected with TMEV (Figure 3F).  To ensure the viral RNA was 
inside the exosomes, the exosomes isolated from TMEV- infected microglia were 
treated with RNAse or proteinase cocktail after isolation and then analyzed for 
viral RNA.  These treated exosomes had similar levels of viral RNA as untreated 
exosomes indicating viral RNA was inside the exosomes (Figure 3E). 
Furthermore, when these treated exosomes were placed on bystander microglia, 
the microglia contained similar levels of viral RNA after 24 hours compared to 
untreated exosomes from TMEV infected microglia (Figure 3G). Finally, we 
wanted to determine whether the viral RNA that was transferred by the 
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exosomes to the bystander microglia was able replicate in the recipient cells.  
The exosomes were isolated from TMEV- infected microglia and placed on 
bystander microglia for 4 hours, the exosomes were removed, and the cells were 
washed.  The bystander microglia were incubated an additional 0, 4, 8, or 20 
hours before being lysed and analyzed for viral RNA.  The viral RNA in the 
bystander microglia increased over time indicating viral replication occurred in 
the recipient cells (Figure 3H).  
Exosomes secreted by virus- infected microglia activate bystander CNS 
cells 
 We have previously shown that microglia infected with TMEV become 
activated immune cells and express innate immune cytokines, including pro-
inflammatory cytokines21.  We wanted to determine whether the exosomes 
secreted by the TMEV- infected microglia could activate uninfected bystander 
microglia.  We have shown above that exosomes secreted by TMEV- infected 
microglia contain viral RNA but do not contain viral proteins.  Exosomes were 
isolated from TMEV- infected microglia and placed on uninfected bystander 
microglia. After 24 hours, the recipient microglia were analyzed for expression of 
cytokines and chemokines.  Bystander microglia exposed to exosomes from 
TMEV-infected microglia increased the expression of type I interferons, IFNα and 
IFNβ, cytokines, IL-6, IL-12, and TNFα, and increased chemokines, CCL2, 
compared to bystander microglia exposed to exosomes from uninfected microglia 
(Figure 4).  The quantity of exosomes added to the bystander microglia (100μg 
per 1x106 cells) was determined based on a dose response to varying amounts 
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of exosomes based on approximately 200μg of exosomes being isolated from 
1x106 TMEV-infected microglia (Figure 5).  Furthermore, exosomes secreted 
from TMEV-infected microglia that were treated with RNAse or proteinase 
cocktail prior to their addition to the bystander microglia showed a similar 
activation of bystander microglia as compared to untreated exosomes (Figure 6).  
These results show that the contents inside the exosomes are activating the 
bystander microglia to increase expression of cytokines and chemokines.  To 
determine activation time course, exosomes were isolated from TMEV-infected 
microglia and added to bystander microglia.  After 4 hours, the microglia cultures 
were washed to remove any exosomes that were not taken up.  The microglia 
were incubated for an additional 0, 4, 8, or 20 hours and then lysed for analysis 
of expression of cytokines and chemokines.  The bystander microglia increased 
expression of cytokines and chemokines over time (Figure 7).   
 The CNS has several resident cells, including astrocytes and neurons, 
which could also take up exosomes secreted by microglia.  Thus, exosomes 
isolated from TMEV- infected microglia were placed on uninfected bystander 
astrocytes.  After 24 hours, the astrocytes were examined for viral RNA and were 
also analyzed for the expression of cytokines and chemokines (Figure 8).   
Exosomes from TMEV-infected microglia transferred viral RNA to the bystander 
astrocytes and activated the astrocytes to express type I interferons, IFNα and 
IFNβ, as well as increase the expression of cytokines, IL-6, IL-12, and TNFα, and 
chemokines, CCL2.  Similarly, exosomes from TMEV- infected microglia were 
placed on uninfected bystander neurons.  After 24 hours, the neurons were 
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examined for viral RNA and for expression of cytokines and chemokines (Figure 
9).  Exosomes from TMEV-infected microglia transferred viral RNA to neurons 
and activated the neurons to express type I interferons, IFNα and IFNβ, 
cytokines, IL-6, IL-12, and TNFα, and chemokines, CCL2.  
Bystander microglia are activated by the viral RNA in exosomes from 
TMEV-infected microglia 
 Since the exosomes contain viral RNA and viral RNA has been shown to 
be recognized by innate immune receptors to activate an innate immune 
response, we wanted to determine whether the viral RNA in the exosomes was 
activating the bystander microglia.  Since TMEV is a single stranded RNA virus, 
the innate immune receptors that recognize single stranded RNA include TLR7 
which signals through MyD8871.  Double stranded RNA is recognized by TLR3 
which signals through TLR adaptor molecule 1 (Ticam1) to induce expression of 
type I interferons.  Double stranded RNA is also recognized by melanoma 
differentiation- associated protein 5 (MDA5) which signals through mitochondrial 
antiviral- signaling protein (MAVS) to induce expression of type I interferons and 
cytokines71.  Thus, microglia were silenced for MyD88, Ticam1, or MAVS prior to 
incubation with exosomes from TMEV-infected microglia (Figure 10).  After 24 
hours, the microglia were analyzed for expression of type I interferons and 
cytokines.  Microglia that were silenced for MyD88 and MAVS had greatly 
reduced expression of IFNα and IFNβ after exposure to TMEV- infected 
exosomes while there was no difference in type I interferon in microglia silenced 
for Ticam1.  In addition, microglia silenced for MyD88 and MAVS also had 
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reduced expression of cytokines, IL-6 and TNFα after exposure to TMEV- 
infected exosomes.  These results show that MyD88 and MAVS which are 
important signaling pathways in the innate immune response to viral RNA were 
necessary for microglia to become activated to express type I interferons and 
cytokines in response to TMEV-infected exosomes. 
 Because the inflammatory response induced by exosomes from TMEV-
infected microglia on bystander cells was prominent and promising, we wanted to 
see if the exosomes alone could generate a similar effect in the CNS of mice as 
seen with direct TMEV infection. In order to observe pathology of demyelinating 
disease, 4 doses of exosomes were given to mice, one dose every other day. 
Intrathecal injection procedure was carefully chosen over intracerebral injection 
because of its less invasiveness. Two days after the last injection, mice brains 
and spinal cords were collected and processed for immunohistochemistry 
staining and RNA Scope in situ hybridization. First, tissue sections were stained 
for myelin peptide, PLP, and microglia marker, Iba1. Myelin loss and significant 
increase in Iba1 expression in the brains and spinal cords of mice injected with 
exosomes from TMEV-infected microglia were observed (Figure 11B, D, F). 
Besides the increase in quantity, microglia from the mice exhibited the typical 
ameboid morphology associated activation status. In comparison, mice injected 
with exosomes isolated from uninfected microglia showed intact myelin and 
without sign of microglia activation (Figure 11A, C, E). Although Iba1 is the 
standard marker for microglia in the CNS during normal condition, events such 
as infections and injuries would compromise the integrity of the BBB to allow the 
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CNS infiltration of monocytes/macrophages, which also express Iba1. Thus, the 
Iba1+ cells could represent both microglia and those infiltrating blood 
mononuclear cells. RNA Scope in situ hybridization was used to detect viral RNA 
(Figure 11F) and pro-inflammatory cytokines (Figure 11G) in the lumbar sections 
of mice injected with exosomes from TMEV-infected microglia. Cells in the CNS 
were co-labeled with viral RNA. More interestingly, those cells and the neighbor 
cells expressed high level mRNA for pro-inflammatory cytokine, Il-1β. Overall, 
these data support previous findings in which viral RNA in exosomes from 
microglia can be taken up by CNS bystander cells. These cells can become 
activated to initiate bystander activation and bystander damage, contributing to 
the demyelinating process. 
Microglia secrete exosomes during TMEV infection in mice that contain 
viral RNA and activate bystander CNS cells 
 The in vitro data showed that microglia infected with TMEV secrete 
exosomes that contain viral RNA that can activate bystander CNS cells, including 
microglia, astrocytes, and neurons to express type I interferons and cytokines.  
Next, we wanted to determine whether microglia infected with TMEV in mice also 
secrete exosomes that contain viral RNA.  SJL mice were infected with TMEV or 
mock infected, and at 2 days post infection, the brain was removed, and 
exosomes were isolated.  The exosomes were analyzed by flow cytometry for 
expression of CD63, exosome marker, and CD11b, microglia (Figure 12A, B).  
Approximately 60% of the exosomes isolated from the brain were derived from 
microglia as determined by CD11b expression, and this was consistent between 
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TMEV- infected and mock- infected mice.  Further analysis of the exosomes from 
TMEV- infected mice determined that the exosomes had MHC class II on the 
surface while exosomes from mock infected mice did not have MHC class II 
(Figure 12C, D).  These results are similar to MHC class II expression on 
microglia during TMEV infection in the brain.  The exosomes isolated from the 
TMEV- infected mice were then sorted based on CD11b expression to isolate 
exosomes derived specifically from microglia.  The exosomes isolated from 
TMEV infected mice brains did not contain viral particles as determined by 
plaque assay and mass spectrometric analysis (Figure 2B, C, and Table 1).  The 
CD11b+ exosomes from TMEV-infected mice contained viral RNA while CD11b- 
exosomes had very little viral RNA (Figure 12F).  Most significantly, the CD11b+ 
exosomes contained the viral genome (Figure 12E).  Next, the CD11b+ 
exosomes from TMEV- infected mice were placed on uninfected microglia in vitro 
to determine whether the viral RNA could be transferred to bystander microglia.  
The CD11b+ exosomes from TMEV-infected mice transferred the viral RNA to 
bystander microglia including the viral genome, while the CD11b- exosomes 
transferred minimal viral RNA (Figure 12E, G).  Furthermore, CD11b+ exosomes 
from TMEV-infected mice were placed on bystander astrocytes and neurons in 
vitro.  Similarly, the CD11b+ exosomes from TMEV-infected mice were able to 
transfer the viral RNA to the bystander astrocytes and neurons (Figure 12 H, I).  
These results show that during TMEV infection of mice microglia secrete 
exosomes that contain viral RNA but not infectious virus particles or viral 
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proteins, and these exosomes can transfer viral RNA to bystander, uninfected 
CNS cells. 
 Since the exosomes secreted from TMEV-infected microglia in vitro 
activated bystander microglia, we wanted to determine whether the exosomes 
secreted by microglia during TMEV infection in mice could activate uninfected 
bystander microglia.  The CD11b+ exosomes isolated from TMEV-infected mice 
at 2 days post infection were transferred to uninfected bystander microglia.  After 
24 hours, the microglia were examined for expression of type I interferons, 
cytokines, and chemokines (Figure 13).  The microglia that were incubated with 
CD11b+ exosomes from TMEV- infected mice increased the expression of type I 
interferons, IFNα and IFNβ, cytokines, IL-6, IL-12, and TNFα, and chemokines, 
CCL2.  Meanwhile, CD11b- exosomes isolated from TMEV-infected mice only 
slightly increased the expression of type I interferons and IL-6 in bystander 
microglia.  Similarly, when CD11b+ exosomes from TMEV-infected mice were 
transferred to bystander astrocytes (Figure 14A-F) and neurons (Figure 14G-L), 
the CD11b+ exosomes increased the expression of type I interferons, cytokines, 
and chemokines in the bystander cells.  These results show that CD11b+ 
exosomes secreted during TMEV infection in mice activate bystander microglia, 
astrocytes, and neurons to express type I interferons, IFNα and IFNβ, cytokines, 
IL-6, IL-12, TNFα, and chemokines, CCL2. 
 Since the exosomes secreted by microglia during TMEV infection in mice 
activated bystander cells in vitro, we wanted to determine whether these 
exosomes could activate an inflammatory response in the brain of a naïve 
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mouse.  CD11b+ exosomes were isolated from TMEV- infected mice at 2 days 
post infection, the CD11b+ exosomes were injected into the brain of naïve 
mouse. At 2 days post injection, the brains were removed and examined for 
expression of viral RNA (Figure 15).  The mice that received the CD11b+ 
exosomes from the TMEV- infected mouse had viral RNA in the brain although at 
a lower level compared to mice directly infected with TMEV.  More interestingly, 
the CD11b+ exosomes injected in the naïve mice brains activated the expression 
of type I interferons, IFNα and IFNβ, as well as induced the expression of 
inflammatory cytokines, IL-6 and TNFα (Figure 15).  Although the levels of 
expression of the cytokines were less compared to directly infected mice, the 
levels of cytokines were significantly increased over the mice that had been 
injected with CD11b+ exosomes from naïve mice.  These results show that 
exosomes secreted by CD11b+ microglia during TMEV infection can transfer viral 













Table 1: Protein analysis in identification of exosomes. Exosomes were 
isolated and purified from TMEV-infected microglia. Mass spectrometry was used 
to analyze protein contact on both surface and inside of exosomes. 
 
 
Supplemental Table I.  Protein Analysis in Identification of Exosomes
Proteins Present in Exosomes Proteins Absent in Exosomes
CD63 antigen Grp94 (HSP90B1)
Integrin alpha-1 (Itga1) Clanexin (CANX)
CD81 antigen Golgi (GM130)
CD9 antigen cytochrome C (cytC)
Tumor susceptibility gene 101 protein (Tsg101) histones (HIST*H*)
Ras-related protein Rab-14 (Rab14) Argonaute/RISC complex (AGO*)
Putative uncharacterized protein (Rab5c) 
Ras-related protein Rab-5A (Rab5a) TMEV viral capsid protein 3 (VP3)
Ras-related protein Rab-5B (Rab5b) TMEV viral protein 3C
Ras-related protein Rab-2A (Rab2a) TMEV viral protein 2C
Ras-related protein Rab-10 (Rab10)
Ras-related protein Rab-18 (Rab18) 
Ras-related protein Rab-7a (Rab7a) 
Ras-related protein Rab-14 (Rab14) 
Annexin A2 (Anxa2)
Cell adhesion molecule 3 (Cadm3) 




Figure 1.  TMEV-infected microglia secrete exosomes that contain 
activation markers.  
Exosomes were isolated from uninfected (A-E) or TMEV infected microglia (F-J).  
The exosomes were labeled with fluorescently labeled antibodies for CD63 (A 
and F), CD11b (B and G), MHC class II (C and H), CD80 (D and I), and CD86 (E 
and J).  The exosomes were analyzed by flow cytometry for expression of 
specific markers as shown in the black line compared to isotype control 
antibodies in the gray line.  (K) Isolated exosomes were analyzed by 
transmission electron microscopy and determined to be 40-80nm.  One 
representative image is shown.  These are representative graphs and images 
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Figure 2. Exosomes isolated from TMEV- infected microglia do not contain 
infectious viral particles.   
Exosomes were isolated from TMEV-infected microglia or mock infected 
microglia.  The exosomes were analyzed by Nanosight for particle size (A).  The 
supernatant removed from TMEV-infected microglia (TMEV Sup) or mock 
infected microglia (Mock Sup), and the exosomes isolated from TMEV-infected 
microglia (TMEV Exo) or mock infected microglia (Mock Exo) were used in a 
plaque assay with BHK cells.  Plaque forming units (PFU) were determined per 
ml of starting supernatant.  The brain was removed from TMEV-infected mice at 
2 days post infection (TMEV brain) or from mock infected mice (Mock brain) and 
homogenized.  The exosomes were isolated from the brains of TMEV infected 
mice at 2 days post infection and then sorted into CD11b+ exosomes (TMEV 
CD11b+ Exo) and CD11b- exosomes (TMEV CD11b- Exo).  Exosomes were 
also isolated from mock infected mice brains (Mock Exo).  The brain 
homogenates and isolated exosomes were used in a plaque assay and plaque 






Figure 3.  Exosomes from TMEV-infected microglia contain viral RNA that 
is transferred to bystander microglia.   
(A) Microglia were infected with TMEV and exosomes were isolated (lane TE).  
Microglia (1x106) were uninfected (lane C), infected with TMEV (lane CT), or 
incubated with exosomes (100ug) from TMEV- infected microglia (lane CTE).  
The cells were lysed 24 hours later, RNA isolated, converted to cDNA, and used 
in PCR analysis with primers for TMEV long (5.4kbp) or short (200bp) products 
or with primers for β-actin.  (B) Exosomes isolated from TMEV-infected microglia 
were fluorescently labeled with 2uM CFSE (green).  The exosomes were placed 
in culture with naive microglia for 2 hours, and the microglia were fixed and 
incubated with fluorescently labeled antibody for CD11b (red).  Exosomes 
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isolated from TMEV- infected microglia were incubated with RNA stain (green) 
and placed on microglia for 2 hours (C) or 4 hours (D).  Microglia were fixed and 
incubated with fluorescently labeled antibody for CD11b (red).  Cells were 
analyzed by confocal microscopy. (E)  Exosomes from TMEV-infected microglia 
were isolated and control treated (PBS), RNAse treated, or proteinase treated. 
The RNA was isolated from the exosomes, converted to cDNA, and used in real 
time PCR with primers for TMEV.  (F) Microglia were uninfected (naïve) or 
infected with TMEV.  Microglia were incubated with exosomes isolated from 
TMEV-infected microglia or uninfected microglia.  The microglia were lysed 24 
hours later, RNA isolated, converted to cDNA, and real time PCR conducted with 
primers for TMEV. (G)  Exosomes were isolated from TMEV- infected microglia 
and control treated (PBS), RNAse treated or proteinase treated prior to putting 
the exosomes into culture with naïve microglia.  The microglia were lysed 24 
hours later and analyzed by real time PCR for TMEV.  (H)  Exosomes were 
isolated from TMEV- infected microglia and placed on naïve microglia.  After 4 
hours, the exosomes were removed and the cells were washed and incubated for 
an additional 0, 4, 12, or 20 hours before being lysed and analyzed by real time 
PCR for TMEV.  Significant difference was determined by one-way ANOVA and 
Bonferroni’s multiple comparison test (p<0.001) based on expression by naïve 
microglia. These are representative graphs from one experiment of six 
independent repeated experiments. 
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Figure 4. Exosomes from TMEV- infected microglia activate bystander 
microglia to express type I interferons and pro-inflammatory cytokines. 
Exosomes were isolated from TMEV-infected microglia or uninfected (naïve) 
microglia (100 ug) and placed on naive microglia (1x106) for 24 hours.  Microglia 
were lysed, RNA isolated, converted to cDNA, and analyzed by real time PCR for 
expression of IFNα (A), IFNβ (B), IL-6 (C), IL-12 (D), TNFα (E), and CCL2 (F).  
Significant difference was determined by the one-way ANOVA and Bonferroni’s 
multiple comparison test (p<0.001) based on unstimulated microglia. These are 
representative graphs from one experiment of five independent repeated 









Figure 5. Exosomes from TMEV-infected microglia activate bystander 
microglia in dose dependent manner.   
Exosomes were isolated from TMEV-infected microglia or mock infected 
microglia.  The exosomes from TMEV- infected microglia were quantified and 
placed on unstimulated microglia (1x106) at concentration of 200ug, 100ug, 20ug, 
or 2ug for 24 hours.  Microglia were lysed, RNA isolated, converted to cDNA, and 
analyzed by real time PCR for expression of TMEV (A), IFNα (B), IFNβ (C), IL-6 
(D), and TNFα (E). Significant difference was determined by the one-way 
ANOVA and Bonferroni’s multiple comparison test (p<0.001) based on 
unstimulated microglia. These are representative graphs from one experiment of 






Figure 6. The content inside of exosomes from TMEV-infected microglia 
activate bystander microglia.   
The exosomes (200ug) from TMEV-infected microglia were control treated, 
RNAse treated, or proteinase treated.  The exosomes were then placed in culture 
with naïve microglia for 24 hours.  After 24 hours, the microglia were lysed, RNA 
isolated, converted to cDNA, and analyzed by real time PCR for expression of 
TNFα (A), IFNβ (B), IL-6 (C), and TNFα (D).  Significant difference was 
determined by the one-way ANOVA and Bonferroni’s multiple comparison test 
(p<0.001) based on unstimulated microglia. These are representative graphs 






Figure 7. The expression of type I interferons and pro-inflammatory 
cytokines increased over time in bystander microglia exposed to exosomes 
from TMEV-infected microglia, starting at 4 hours.  
Exosomes (200ug) were isolated from TMEV- infected microglia and placed on 
naïve microglia.  After 4 hours, the exosomes were removed, and the cells were 
washed.  The microglia were incubated for an additional 0, 4, 8, or 12 hours 
before being lysed and analyzed by real time PCR for expression of IFNα (A), 
IFNβ (B), IL-6 (C), and TNFα (D).  Significant difference was determined by the 
one-way ANOVA and Bonferroni’s multiple comparison test (p<0.001) based on 
unstimulated microglia. These are representative graphs from one experiment of 




Figure 8.  Exosomes from TMEV-infected microglia activate bystander 
astrocytes.  
Exosomes were isolated from uninfected (naïve) microglia or TMEV-infected 
microglia and placed on naive astrocytes for 24 hours. Astrocytes were lysed, 
RNA isolated, converted to cDNA, and analyzed by real time PCR for expression 
of TMEV (A), IFNα (B), IFNβ (C), IL-6 (D), IL-12 (E), TNFα (F) and CCL2 (G).  
Significant difference was determined by the one-way ANOVA and Bonferroni’s 














Figure 9.  Exosomes from TMEV-infected microglia activate bystander 
neurons.   
Exosomes were isolated from uninfected (naïve) microglia or TMEV-infected 
microglia and placed on naive neurons for 24 hours. Neurons were lysed, RNA 
isolated, converted to cDNA, and analyzed by real time PCR for expression of 









Significant difference was determined by the one-way ANOVA and Bonferroni’s 
multiple comparison test (p<0.001) based on unstimulated microglia. These are 




Figure 10.  Bystander microglia are activated by viral RNA in exosomes 
from TMEV-infected microglia via innate immune receptors.   
Microglia were transfected with siRNA for MyD88, TICAM-1, MAVS, or control (6 
hours).  Exosomes were isolated from TMEV- infected microglia and placed on 
the transfected microglia for 24 hours.  Microglia were lysed, RNA isolated, 
converted to cDNA, and analyzed by real time PCR for expression of IFNα (A), 
IFNβ (B), IL-6 (C), and TNFα (D).  Significant difference was determined by the 








control siRNA transfected microglia. These are representative graphs from one 
experiment of three independent repeated experiments. 
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Figure 11. Exosomes from TMEV-infected microglia transfer viral RNA to 
bystander cells, promote microglia activation, myelin loss, and 
inflammation in the CNS of mice. 
Naïve mice were injected intrathecally with 100ug exosomes from TMEV-infected 
microglia (TMEV exosomes, B, D, F) or unstimulated microglia (naïve exosomes, 
A, C, E) for every other day for the total of 4 injections. Mice (3 mice/group) were 
sacrificed 2 days after the last injection. Brains and spinal cords were sectioned 
and fluorescently stained for proteolipid protein (PLP, red) or Iba1 (microglia 
marker, red), and DAPI (blue). Images were taken at 10x magnification. Scale 
bar=80um. (F and G) RNAScope in situ hybridization technique was done on 
lumbar sections from mice injected with exosomes from TMEV-infected 
microglia. (F) TMEV RNA (green) was detected in microglia (red), DAPI (blue). 
(G) TMEV RNA (green) and IL-1β (red) are localized in microglia (blue). Images 




Figure 12. Exosomes secreted by microglia during TMEV infection of mice 
contain viral RNA that can be transferred to bystander CNS cells.  
Exosomes were isolated from the brains of TMEV- infected mice at day 2 post 
infection (3 mice per group).  The exosomes were labeled with fluorescently 
labeled antibodies for CD63, CD11b, and MHC class II. The exosomes were 
analyzed by flow cytometry for CD63 (A) and CD11b (B) and MHC class II in 
CD11b- exosomes (C) and CD11b+ exosomes (D) with the specific antibodies in 
black lines and isotype control antibodies in gray.   (E) Mice were infected or 










mock infected with TMEV.  At 2 days post infection, exosomes were isolated 
from the brains and sorted for CD11b+ exosomes.  RNA was isolated from the 
CD11b+ exosomes from mock infected mice (C) and TMEV-infected mice (TE).  
RNA was converted to cDNA and used in PCR analysis with primers for TMEV 
long (5.4kbp) or short (200bp) products or with primers for β-actin.  Microglia 
were incubated with CD11b+ exosomes isolated from the brains of TMEV- 
infected mice (lane CTE).  The cells were lysed 24 hours later and RNA isolated, 
converted to cDNA and used in PCR analysis. (F) At day 2 post infection, 
exosomes were isolated from TMEV- infected mice brains and sorted into 
CD11b+ and CD11b- exosomes.  The exosomes were analyzed for TMEV using 
real time PCR.  (G-I) The exosomes isolated from TMEV- infected mice brains 
were sorted into CD11b+ and CD11b- exosomes and placed on unstimulated 
cultures of microglia, astrocytes, and neurons.  After 24 hours, the cells were 
lysed, RNA isolated, converted to cDNA and analyzed by real time PCR for 
TMEV in microglia (G), astrocytes (H), and neurons (I).  These are representative 




Figure 13. Exosomes secreted by microglia during TMEV infection in mice 
activate bystander microglia.   
Exosomes were isolated from the brains of TMEV- infected mice at 2 days post 
infection (3 mice per group).  The exosomes from the brains of TMEV- infected 
mice and naïve mice were sorted for CD11b+ and CD11b- exosomes which were 
then placed on unstimulated microglia.  After 24 hours, the microglia were lysed, 
RNA isolated, converted to cDNA, and used in real time PCR with primers for 
IFNα (A), IFNβ (B), IL-6 (C), IL-12 (D), TNFα (E), and CCL2 (F). Significant 
difference was determined by the one-way ANOVA and Bonferroni’s multiple 
comparison test (p<0.001) based on microglia that were incubated with 
exosomes secreted by microglia in naive mice. These are representative graphs 










Figure 14. Exosomes secreted by microglia during TMEV infection in mice 
activate bystander CNS cells.   
Exosomes were isolated from the brains of TMEV- infected mice at 2 days post 
infection or from naïve mice (3 mice per group).  The exosomes were sorted for 















After 24 hours, the astrocytes (A-F) and neurons (G-L) were lysed, RNA isolated, 
converted to cDNA, and used in real time PCR with primers for IFNα (A and G), 
IFNβ (B and H),  IL-6 (C and I), IL-12 (D and J), TNFα (E and K), and CCL2 (F 
and L). Significant difference was determined by the one-way ANOVA and 
Bonferroni’s multiple comparison test (p<0.001) based on naive astrocytes or 
neurons.  These are representative graphs from one experiment of three 
independent repeated experiments.  
 
 
Figure 15.  Exosomes secreted by microglia during TMEV infection in mice 
activate an inflammatory response in naïve mice.   
Exosomes were isolated from the brains of TMEV- infected mice at 2 days post 
infection or from naïve mice (3 mice per group).  The exosomes were sorted for 
CD11b+ exosomes, and the CD11b+ exosomes were injected into the brain of 
naïve mice.  At 2 days post injection, the brains were removed from the mice (3 














PCR with primers for TMEV (A), IFNα (B), IFNβ (C), IL-6 (D), IL-12 (E), and TNFα 
(F).  As comparison, the brains were removed from naïve mice or mice at 2 days 
post TMEV infection, and RNA was isolated, converted to cDNA and used in real 
time PCR.  Significant difference was determined by the one-way ANOVA and 
Bonferroni’s multiple comparison test (p<0.001) based on the naïve mouse brain.   
DISCUSSION 
Microglia are the immune resident population of the CNS.  We have 
previously shown that microglia become persistently infected with TMEV.  These 
studies show that TMEV-infected microglia secrete exosomes that contain viral 
RNA which can be transferred to uninfected CNS resident cells, including 
microglia, astrocytes, and neurons.  We have previously shown that TMEV- 
infected microglia become activated to express type I interferons and pro-
inflammatory cytokines and chemokines20, 21.  In these studies, we show that 
exosomes from TMEV- infected microglia contain viral RNA but do not contain 
viral particles or viral proteins.  These exosomes can be taken up by uninfected 
bystander microglia, and the viral RNA in the exosomes were recognized by 
innate immune receptors in the uninfected bystander microglia which activated 
the microglia to express type I interferons and pro-inflammatory cytokines.   
Likewise, exosomes secreted from TMEV- infected microglia also activated other 
CNS bystander cells including astrocytes and neurons to express type I 
interferons and pro-inflammatory cytokines and chemokines.  Since the in vitro 
studies were promising, we wanted to validate whether exosomes secreted by 
microglia during TMEV infection in mice could have similar effects on bystander 
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cells.  Exosomes from microglia were isolated from the brains of mice by sorting 
isolated exosomes for CD11b+ exosomes.  These studies showed that exosomes 
secreted by microglia during TMEV infection in mice contain viral RNA but do not 
contain viral particles or viral proteins.  The exosomes secreted by microglia 
during TMEV infection could activate bystander microglia, astrocytes, and 
neurons to secrete type I interferons and pro-inflammatory cytokines.  Most 
importantly, exosomes secreted by microglia during TMEV infection in mice could 
induce an inflammatory immune response when injected into a naïve mouse.  
These results showed that TMEV- infected microglia secrete exosomes that not 
only transfer viral RNA to bystander uninfected CNS cells but also activates 
bystander cells to express pro-inflammatory cytokines and chemokines 
associated with neuroinflammation. 
 Following TMEV infection in SJL mice, infectious virus loads are very high 
in the brain for the first 1-3 days post infection followed by a rapid spread to the 
spinal cord.  The virus remains persistent in both the brain and spinal cord 
throughout the lifetime of the animal26. Microglia have been shown to be the 
persistently infected cells during TMEV, however, microglia produce very few 
infectious viral particles during infection72.  Since microglia play an important role 
in the persistent virus infection, these studies focused on TMEV-infected 
microglia.  We wanted to determine whether TMEV- infected microglia secrete 
exosomes that may contain viral products.  In order to isolate exosomes that 
excluded viral particles, we used a method to isolate exosomes that does not 
include high speed centrifugation which would pellet the viral particles.  TMEV is 
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a non-enveloped virus around 40-50nm in size.  Our method yielded purified 
exosomes as verified by TEM staining for morphology, as verified for CD63 
expression by flow cytometry and mass spectrometry, and as verified for particle 
size by Nanosight (120nm).  The isolated exosomes did not contain viral particles 
as verified by TEM staining which showed no viral particles isolated with the 
exosomes and no viral particles in exosomes, by plaque assays which showed 
no infectious particles isolated with the exosomes and no viral particles in 
exosomes, and by mass spectrometry which showed no viral proteins in 
exosomes.  Since the exosomes do not contain viral particles, we wanted to 
determine whether the exosomes from TMEV-infected microglia contain viral 
RNA.  TMEV is a small positive single- stranded RNA virus.  The exosomes 
secreted from TMEV- infected microglia contained not only viral RNA but the 
whole viral genome.  To further determine whether microglia were secreting 
exosomes during TMEV infection in mice, we isolated exosomes from the brains 
of TMEV infected mice at 2 days post infection.  Since exosomes from microglia 
were determined to have CD11b on their surface, we sorted microglia-secreted 
exosomes from the whole brain exosomes using CD11b as a marker.  Most 
interestingly, the exosomes secreted by microglia during TMEV infection in the 
brain contain viral RNA, including the entire TMEV genome.  Meanwhile, the 
exosomes from the brain of TMEV- infected mice that were secreted by other 
cells (CD11b-), not microglia, contained little or no viral RNA suggesting the main 
source of exosomes that contain viral RNA in the brain during TMEV infection are 
secreted by microglia.  The exosomes secreted by microglia during TMEV 
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infection could transfer the viral RNA to uninfected microglia, and the viral RNA 
replicated in the recipient cells.  Similarly, exosomes secreted by microglia during 
TMEV infection could transfer viral RNA to uninfected bystander astrocytes and 
neurons.  These results show that exosomes secreted by microglia during TMEV 
infection can transfer viral RNA to uninfected cells independent of viral particles.  
Furthermore, the viral RNA transferred by the exosomes could replicate in the 
recipient bystander cells.  Most interestingly, exosomes may transport viral RNA 
between cells during TMEV infection as a means to evade the immune response, 
especially virus-specific antibodies, and enable virus persistence.    
 Microglia infected with TMEV produce type I interferons which have been 
shown to have a direct effect on development of TMEV- induced demyelinating 
disease41.  The exosomes secreted by microglia during TMEV infection could 
activate the expression of type I interferons, IFNα and IFNβ, in the uninfected 
bystander microglia.  We have previously shown that microglia express several 
innate immune receptors that recognize viral RNA20.  Since TMEV is a single 
stranded RNA virus, the innate immune receptors that could recognize the RNA 
include TLR3, TLR7 and MDA5.  Each of these receptors activates a distinct 
signaling pathway to promote transcription of type I interferons.  Silencing MyD88 
which is activated by TLR7 or silencing MAVS which is activated by MDA5 led to 
reduced expression of type I interferons in microglia that were exposed to 
exosomes secreted by microglia during TMEV infection.  These results show that 
viral RNA in the exosomes were recognized by innate immune receptors in the 
bystander microglia which activated the expression of type I interferons.  Further, 
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exosomes secreted by microglia during TMEV infection could also activate the 
expression of type I interferons in bystander astrocytes and neurons.  Type I 
interferons have direct anti-viral activity, thus, the expression of type I interferons 
in these bystander cells may protect these cells from a damaging virus infection, 
especially for neurons. 
 Microglia infected with TMEV become activated to express pro-
inflammatory cytokines, chemokines, and effector molecules associated with 
neuroinflammation.  The exosomes secreted by microglia during TMEV infection 
could also induce the expression of pro-inflammatory cytokines, IL-6, IL-12 and 
TNFα, and chemokines, CCL2, in bystander uninfected microglia.  The 
expression of cytokines and chemokines was reduced when innate immune 
signaling pathways involved in recognition of viral RNA were silenced, however, 
the expression was not completely reduced.  This suggests that some expression 
of cytokines and chemokines is induced by the innate immune response to viral 
RNA, however, there are many other components in the exosomes secreted by 
microglia during TMEV infection, including miRNA and proteins, which may be 
also be activating the expression of cytokines and chemokines in the bystander 
cells.  However, exosomes secreted by other cell types in the CNS (CD11b-) 
during TMEV infection were unable to activate bystander microglia.  Further, the 
exosomes secreted by microglia during TMEV infection could also activate 
bystander astrocytes and neurons to express cytokines and chemokines.  These 
results show that exosomes secreted by microglia during TMEV infection activate 
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bystander uninfected cells to express pro-inflammatory cytokines and 
chemokines which may contribute to neuroinflammation during infection. 
    We have previously shown that microglia become activated following 
TMEV infection to increase expression of co-stimulatory molecules and MHC 
class II21.  Interestingly, exosomes secreted by microglia during TMEV infection 
had increased levels of co-stimulatory molecules, CD80, CD86, CD40, on the 
surface compared to exosomes secreted by microglia during mock infection.  
Further, exosomes secreted by microglia during TMEV infection have MHC class 
II.  These results suggest that exosomes can also have proteins on their surface 
which are similar to the activation state of the cells from which they are derived.  
In addition, the exosomes isolated from the brain of TMEV infected mice were 
about 60% CD11b+ which suggests that the majority of exosomes in the CNS are 
derived from microglia but also suggests that other CNS cells also secrete 
exosomes which may have an effect during virus infection.  For this reason, 
these studies isolated CD11b+ exosomes to focus on exosomes secreted from 
microglia. 
 TMEV infection in mice leads to neuroinflammation which contributes to 
the development of demyelinating disease.  Exosomes secreted by microglia 
during TMEV infection were shown to activate uninfected bystander microglia, 
astrocytes, and neurons to express pro-inflammatory cytokines and chemokines 
associated with neuroinflammation.  However, to determine the effect of 
exosomes on neuroinflammation in the brain, the exosomes secreted by 
microglia during TMEV infection in mice were injected into naïve mice.  First, 
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multiple intrathecal injections of exosomes from TMEV-infected microglia into 
naïve mice could induce similar consequences seen with direct TMEV infection 
including microglia/monocyte/macrophage activation and myelin loss. Since Iba1 
labels monocytes and macrophages as well, we could not rule out the possibility 
that exosomes from infected microglia could promote an influx of immune cells 
into the CNS, and additional works are needed to help distinguish between these 
cell types. Viral RNA were also detected in the same area with high IL-1β 
expression. In a different experiment, exosomes secreted by microglia isolated 
from mice during TMEV infection promoted the expression of pro-inflammatory 
cytokines and chemokines in the naïve mouse with a single intracerebral 
injection.  In addition, the exosomes secreted by microglia during TMEV infection 
could transfer viral RNA and induce the expression of type I interferons in the 
brain of the naïve mice.  These results show that exosomes secreted by 
microglia during TMEV infection can transfer viral RNA and can promote 
neuroinflammation in a naïve mouse brain suggesting that exosomes may play 
an important role in virus persistence and neuroinflammation during TMEV 
infection.  These results suggest that exosomes secreted by microglia during 
persistent virus infection can promote neuroinflammation associated with 
development of neurological diseases.  Thus, exosomes secreted by microglia 
may represent a novel mechanism for viral persistence and chronic 
neuroinflammation. 
MATERIALS AND METHODS 
Mice 
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Female SJL mice age 5-6 weeks were purchased from Envigo (Madison, 
WI).  Pregnant SJL/J mice (15-17 days) were purchased from Enivgo.  Neonatal 
SJL mice were used for primary cell isolation.  The mice were housed at 
University of Minnesota Research Animal Resource Center accredited by the 
American Association for Accreditation of Laboratory Animal Care.  The animals 
are handled according to university and Animal Care and Use Committee 
approved protocols.   
Isolation and culture of CNS cells  
Isolation of primary glial cultures from neonatal mice was performed, as 
previously described21.  Briefly, brains were removed from 1 to 3 days old mice, 
and the meninges were removed.  The left and right hemispheres of the brain 
were gently dissociated in a nylon mesh bag.  The cells were resuspended in 
DMEM-F12 media (Lonza) supplemented with 10% FCS (Invitrogen Life 
Technologies) and 100U/ml penicillin and 100μg/ml streptomycin (Invitrogen Life 
Technologies).  The cells were seeded in poly(D-lysine) (Sigma- Aldrich) coated 
tissue culture flasks and incubated at 37C.  After 10-14 days of incubation, 
microglia were removed from the astroglial layer by shaking the flasks on an 
orbital shaker for 24 hours.  The primary microglia were removed from the flask 
and placed in DMEM (Invitrogen Life Technologies) supplemented with 10% 
exosome free FCS and 3ng/ml rGM-CSF (R&D Systems).  The microglia were 
seeded in 24-well plates coated with poly(D)lysine.  Astrocytes were cultured in 
supplemented DMEM-F12 media with exosome free FCS as described above.  
For neurons, the brain tissue was dissociated with 0.25% trypsin for 15 minutes, 
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and the cell suspension was placed in laminin coated flasks with B27 
supplemented neurobasal media (Gibco, Invitrogen).  The microglia were 
transfected with siRNA specific for MyD88, Ticam1, or MAVS, SMARTpool 
siRNA (5μM), or siCONTROL (Dharmacon) using Dharmafect 4 following the 
protocol provided by Dharmacon.  
TMEV infection   
SJL female mice were intracranially injected with 2X106 PFU of BeAn 
strain of TMEV.  Microglia were infected with the BeAN strain of TMEV at a 
multiplicity of infection of 5 in serum- limited DMEM for 24 hours as previously 
described21.  
Exosome isolation and analysis 
Cell culture media was removed from the cells and centrifuged at 2,000xg 
to remove cellular debris.  Total exosome isolation reagent for cell culture 
(Invitrogen) was added to the supernatant (1:2 ratio) and incubated overnight at 
4°C.  The exosomes were pelleted the next day by centrifuging at 10,000xg for 
one hour per the protocol (Invitrogen).  For isolating exosomes from brains, the 
brains were dissociated through a 70μM filter into 3ml Hank’s balanced salt 
solution. The homogenate was then centrifuged two times at 2,000xg to remove 
cells and debris.  The exosomes were isolated from the cleared homogenate with 
the isolation reagent as described above. The exosomes were then incubated 
with antibody for CD11b conjugated to magnetic beads and separated on a 
column per manufacturer protocol (Miltenyi).  To determine the size of the 
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exosomes, exosomes were resuspended in PBS and analyzed on a Nanosight 
N300 (Malvern).  To determine purity, exosomes were imaged on a transmission 
electron microscope (TEM).  Briefly, the exosomes were fixed with 2% 
glutaraldehyde for one hour and then absorbed onto a glow discharged carbon-
Formvar coated 200-mesh copper grids for 5 minutes.  Grids were washed twice 
with water and stained with 2% uranyl acetate twice for 30 seconds.  TEM 
imaging was performed on a Tecnai G2 F30 instrument.  Exosomes were 
analyzed by flow cytometry for surface protein expression.  Briefly, exosomes 
were incubated with aldehyde/sulfate latex beads (Invitrogen) per the 
manufacturer protocol.  The exosomes were then incubated with fluorescently 
labeled antibodies for CD45, CD11b, CD63, I-As, CD80, and CD86.  The 
exosomes were washed and analyzed on LSRII (BD).  Isolated exosomes were 
also analyzed for CD63 by western blot (BioRad) following lysis using Total 
Exosome RNA and protein isolation kit (Life Sciences). Florescent imaging of 
exosomes was conducted by labeling exosomes with carboxyfluorescein 
succinimidyl ester (2μM) or SYTO RNA select (Thermo Fisher Scientific).  
Microglia were labeled with fluorescently labeled antibody for CD11b and imaged 
on Olympus confocal microscope. Additional protein analysis was conducted 
using mass spectrometry.  Proteins were separated on 4-12% Bis-Tris gels 
(Invitrogen).  Cysteine bonds were reduced and alkylated with 10nM DTT in 
50mM ammonium bicarbonate and 55mM iodoacetamide:50mM NH4HCO3.  
Proteins were digested in 50mM NH4HCO3, 5mM CaCl2, 5ng/μl trypsin.  The 
samples were eluted with 60:40 acetonitrile: H2O, 0.1% trifluoroacetic acid 
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before analysis on Thermo Orbitrap Elite mass spectrometer at the University of 
Minnesota Center for Mass Spectrometry.  To determine concentration of 
exosomes, Bradford assay was performed.  Isolated exosomes were incubated 
with RNAse (100ng/ml) (Thermo Fisher Scientific), or trypsin (1mg/ml) 
(Mediatech) and pepsin (10μg/ml) (Sigma) for 10 minutes at 37C and then 
washed with PBS before analysis or adding to the cells.  Isolated exosomes 
(100μg) were added to cultured cells (1x106) or injected intracranially (500μg) 
into a mouse.  
Multiple intrathecal injections, Immunohistochemistry staining (IHC), and 
RNA SCope 
 Exosomes were isolated from TMEV-infected microglia or uninfected 
microglia. 100ug exosomes were intrathecally injected into naïve mice every 
other day, for 8 days. On day 10, mice were sacrificed, brains and spinal cords 
were perfused with cold PBS and fixed with 4% paraformaldehyde. Tissues were 
paraffin-embedded, sectioned at 5 micron-thick, and stained for microglia marker 
Iba1 (Wako, 1:1000) and PLP (Abcam, 1:1000). For RNA Scope was used to 
detect TMEV RNA, Igtam (microglia marker), and IL-1β according to the 
manufacturer (ACD Bio). Images were captured with an Olympus BX51 confocal 
microscope. 
RNA isolation and PCR analysis 
RNA was isolated from exosomes using the Total Exosome RNA and 
protein isolation kit (Life Sciences).  RNA was isolated from microglia, astrocytes, 
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and neurons using SV Total RNA Isolation kit which contains a DNAse reaction 
(Promega).  RNA was isolated from brain tissue using Trizol protocol followed by 
DNAse digestion (Thermo Fisher Scientific).  First strand cDNA was generated 
from 1μg of total RNA using oligo(dT)12-18 primers and Advantage for RT-PCR kit 
in a final volume of 100μl (Clontech).  Real- time PCR was conducted in triplicate 
with Rotor-Gene SYBR green RT-PCR kit (Qiagen).  Briefly, 0.5μM primers, 1X 
SYBR Green reagent, and 2μl of cDNA were combined in 10μl reactions.  The 
primers for TMEV, cytokines, chemokines, and effector molecules were 
previously described (2, 11).  Real time PCR was conducted on a Rotor-Gene 
Qiagen Q instrument using hot start with cycle combinations, 40 cycles: 95°C for 
15s; 60°C for 20s; 72°C for 15s, followed by a melt from 75°C to 95°C.  
Quantitation of the mRNA was based on standard curves derived from cDNA 
standards for each primer pair.  Positive and negative cDNA controls were used 
for each primer pair using cells known to express or not express the specific 
mRNA.  Samples from different groups were normalized based on expression of 
β-actin.  All samples were run in triplicate for each primer pair.  Statistical 
analysis comparison between groups was determined by one-way ANOVA and 
Bonferroni’s multiple comparison test (p<0.001).  PCR for viral genomes was 
conducted using cDNA in 25μl reactions with TMEV primers (0.5μM), dNTPs 
(200μM), 1X reaction buffer, and Q5 high fidelity DNA polymerase (0.02U/μl) 
(New England BioLabs) on Eppendorf Mastercycler with a hot start and 40 
cycles: 95°C for 30s; 60°C for 30s; 72°C for 8m, followed by a 20-minute 
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extension.  PCR products were separated on 0.8% agarose gel with Sybr Safe 



















Exosomes from microglia sustain viral persistence and 
neuroinflammation during TMEV-induced demyelinating 
disease in mice   
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BACKGROUND  
Viral persistence is important in sustaining inflammatory cues that lead to 
irreversible damage and development of neurological diseases such as 
MS73.  TMEV is a ssRNA virus that belongs to the Picornavirus family and is 
naturally neurotropic in mice. TMEV (BeAn 8386 strain) infection of susceptible 
mice (SJL strain) leads to persistent infection of microglia and development of 
chronic progressive demyelinating disease in the central nervous system (CNS) 
of mice73. TMEV-induced demyelinating disease (TMEV-IDD) has been a useful 
murine model to study the pathogenesis of MS, particularly the primary 
progressive type. The clinical symptoms in TMEV-IDD including spastic hindlimb 
paralysis is comparable to progressive MS in human74. TMEV-IDD is described 
as a biphasic disease11. In the acute phase of infection, the immune response 
against the virus is driven primarily by activation of innate immune cells and 
TMEV-specific CD4+T cells49. Nevertheless, viral clearance is inefficient in 
susceptible mice, which leads to viral persistence and development of a chronic 
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phase causing demyelination due to neuroinflammation and myelin-specific 
CD4+T cells49.  
Microglia are self-regenerative CNS-resident macrophages that migrate to 
the brain and spinal cord during early development18. As innate immune cells, 
they serve as the first line of defense in the CNS by orchestrating inflammation 
upon the recognition of pathogen-associated molecular pattern molecules by 
innate immune receptors such asToll-like receptors (TLRs)20. TMEV-infected 
microglia secrete a large amount of type I IFNs (IFNα and IFNβ), pro-
inflammatory cytokines (IL-6, IL-12, and TNFα), and chemokines (CCL2, CCL3, 
and CCL5). The chemokines attract infiltrating immune cells such dendritic cells 
and monocytes/macrophages to enter the CNS to partake in the inflammatory 
milieu. Microglia also express surface co-stimulatory molecules CD80, CD86, 
CD40 and MHC class II to present viral and myelin antigens to CD4+ T cells21. 
Neuroinflammation persistently elicited by chronic viral infection can lead to 
bystander damage of neuronal structure, release of myelin epitopes, and 
consequently, demyelinating disease.  
Exosomes have been shown to be exploited by viruses, specifically 
herpesviruses and hepatitis viruses for their transmission and latency61, 62, 75, 
76. Our previous studies showed that microglia from TMEV-infected mice 
produced exosomes during the acute phase contain TMEV RNA and genome 
that could be transferred to uninfected bystander cells, independent of viral 
particles (Chapter 2). Moreover, these exosomes could induce an innate immune 
response in the uninfected cells and inflammation in the CNS of naive mice 
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(Chapter 2). These exciting data suggested that exosomes from microglia 
isolated during the acute infection may play an important role in upholding viral 
infection and neuroinflammation. However, TMEV-IDD is a complex model just 
as human MS, the profile and functions of exosomes collected 2 days after 
infection do not represent the exosomes collected at the chronic demyelinating 
disease phase. We hypothesized that exosomes secreted from microglia during 
the chronic phase of TMEV-IDD contain viral RNA which maintain persistent 
TMEV infection in the CNS and neuroinflammation by activating surrounding 
cells, contributing to demyelination. In summary, we found that during the chronic 
phase, exosomes isolated from microglia from the brains and spinal cord 
continued to contain replication-competent viral RNA. Further, these exosomes 
could continue to stimulate both bystander CNS resident and infiltrating cells to 
secrete type I IFNs, pro-inflammatory cytokines, and chemokines. Most 
importantly, these exosomes could induce an inflammatory response in recipient 
naïve mice brains. All of these findings provide a new insight into the 
mechanisms of how viruses can be persistent in the CNS via exosomes and 
continue to cause immune-mediated demyelinating disease. 
RESULTS 
Microglia secrete exosomes containing viral RNA during TMEV-IDD 
Exosomes are constitutively secreted by cells as a means of 
communicating with other cells through cytoplasmic material exchange. We 
decided to look at exosomes secreted by microglia (microglia exosomes) from 
the brains and spinal cords separately because the microglia reside in the brain 
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have been reported to exhibit phenotypical and functional differences from the 
microglia reside in the spinal cord77, 78.   Microglia exosomes were collected from 
both brains and spinal cords of mice at 63 days post TMEV infection i.e. during 
TMEV-IDD phase or age match naïve control mice using the standard 
procedures established by our lab, described in Chapter 2. Isolated microglia 
exosomes were identified by flow cytometry, western blot, and mass 
spectrometry. The size of microglia exosomes ranged from 30 to 150nm, verified 
by Nanosight (data not shown). The isolated microglia exosomes from both 
groups expressed exosomal marker CD63 (Figure 16A-D). Microglia exosomes 
isolated from the brains and spinal cords of mice during TMEV-IDD expressed 
higher level of surface activation molecules MHC class II, costimulatory 
molecules, CD80, CD86, and CD40 in comparison to naïve microglia exosomes 
(Figure 16E-L). Mass spectrometry revealed that these microglia exosomes 
expressed microglial marker, CD11b, exosome specific markers, CD63, CD9, 
CD81, TSG101, Rab, while lacking markers associated with other subsets of 
extravesicular vesicles (data not shown). 
Next, we wanted to look into the content of microglia exosomes secreted 
during the full course of TMEV infection. From previous studies, microglia 
exosomes secreted 2 days post infection contain TMEV RNA/genome. Since 
TMEV establish a persistent infection in microglia, we queried whether microglia 
continue to encapsulate viral RNA inside exosomes throughout the full course of 
TMEV infection (approximately 96 days). Microglia exosomes were isolated from 
mice brains and spinal cords at 10 critical time points of TMEV-infection (1, 2, 3, 
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4, 7, 10, 14, 28, 42, 63, and 96 dpi). The microglia exosomes consistently 
contained viral RNA starting from day 1 until day 96 post infection (Figure 17A). 
The viral RNA level started high and then gradually decreased with no significant 
difference between the microglia exosomes from brains versus spinal cords at 
any given time point. Since we wanted to study the microglia exosomes 
produced during the chronic demyelinating disease phase, we focused on the 
microglia exosomes from 63dpi brains and spinal cords. Two pairs of primers 
were used to detect different regions on TMEV genome, 200bp upstream region 
and 5.4kbp coding region in the TMEV genome.  The data showed that microglia 
exosomes isolated during TMEV-IDD contain viral RNA and genome (Figure 
17B, C). The microglia exosomes from naïve brains were used as the control in 
the experiments because there was no any difference between exosomes from 
naïve brains and exosomes from naïve spinal cords.  These findings indicated 
that microglia exosomes contain viral RNA/genome not only shortly after TMEV 
infection, but also throughout the TMEV-IDD. These studies suggested 
exosomes could be a way that viruses exploit to persist in host.  
Viral RNA in microglia exosomes secreted during TMEV-IDD can be 
transferred to bystander uninfected CNS cells 
 One unique feature of exosomes is their host-derived cell membrane, 
which allows them to be endocytosed by a wide range of cell types, thus 
facilitating material exchange, including viral RNA. Microglia exosomes (100ug) 
isolated from mice brains and spinal cords during TMEV-IDD were added to 
uninfected microglia (1x106 cells) and cells were lysed after 24 hours of 
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incubation. Real-time PCR detected viral RNA transcripts in the bystander 
uninfected microglia after being exposed to microglia exosomes (Figure17D). 
Moreover, the viral RNA in the bystander microglia was able to replicate as the 
shown by level of viral RNA in cells amplified over the course of 20 hours (Figure 
17G). Next, we investigated whether exosomes can be taken up and transfer 
viral RNA to other cell types in the CNS such as astrocytes and neurons. Again, 
microglia exosomes were added onto primary astrocytes (1x106 cells) and 
neurons (1x106 cells) and lysed the cells after 24 hours of incubation. Similar to 
microglia, astrocytes (Figure 17E) and neurons (Figure 17F) could take up the 
exosomes and obtain the viral RNA. These results suggest that microglia 
exosomes are capable of effectively transferring viral RNA to bystander cells, 
suggesting another persistence mechanism whereby infected cells could secrete 
exosomes containing viral RNA into the microenvironment which can be picked 
up by surrounding uninfected cells to facilitate the spread. 
Viral RNA in microglia exosomes secreted during TMEV-IDD can activate 
bystander CNS cells 
Microglia can be infected with TMEV in vitro and in vivo to become 
activated immune cells. The chronic inflammatory response against the virus is 
the key in TMEV-IDD pathogenesis31. We wanted to determine whether 
exosomes secreted from microglia isolated during the TMEV-IDD could exert a 
activate bystander CNS cells since they contain viral RNA. Microglia exosomes 
were isolated from mice brains and spinal cords during TMEV-IDD. Microglia 
exosomes were added to uninfected microglia, astrocytes, and neurons for 24 
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hours before getting lysed for RNA analysis. The number of exosomes added to 
the cells was determined by dose response curve experiments from our previous 
study (Chapter 2). Bystander cells were lysed for the real-time PCR analysis of 
type I IFNs, cytokines, chemokines, and effector molecules expression. These 
molecules are common markers associated with inflammation. First, the 
bystander microglia incubated with microglia exosomes from mice with TMEV-
IDD expressed a higher level of type I IFNs, IFNα and IFNβ, pro-inflammatory 
cytokines, IL-1β, IL-6, IL-12, TNFα, and chemokines, CCL2, in comparison to 
cells incubated with to the microglia exosomes from naïve mice (Figure 18). 
Similarly, astrocytes (Figure 19A-F) and neurons (Figure 19G-L) also 
upregulated type I IFNs, IFNα and IFNβ, IL-1β, IL-6, TNFα, CCL2 after being 
incubated with microglia exosomes isolated from mice during TMEV-IDD.  
The inflammatory response in bystander microglia were activated through 
innate immune receptors in response to viral RNA in exosomes 
The inflammatory response can be triggered by a wide range of factors 
through the innate immune sensors on the surface and inside cells. Exosomes 
can package and deliver a myriad of host cell-derived materials to the recipient 
cells. In previous studies, we showed that the bystander cells become activated 
by viral RNA in exosome secreted by TMEV-infected cells. Exosomes from 
microglia infected with ultraviolet-inactivated TMEV were not able to elicit an 
immune response in bystander cells (data not shown). The current studies 
looked at microglia exosomes isolated during TMEV-IDD which may contain 
materials specific to chronic disease which acute phase may not have. Thus, we 
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wanted to determine whether viral RNA was still the key component in eliciting an 
innate immune response in bystander cells. To address this question, the innate 
receptors, MyD88 and MAVS, were silenced in microglia using a pool of four 
individual siRNAs for each receptor to assure an efficient knock-down. Then, 
microglia exosomes from TMEV-IDD mice were added to silenced cells for 24 
hours before the cells were lysed for the PCR analysis. As the result, the 
expression of type I IFNs, IFNα and IFNβ, cytokines IL-1β, IL-6, TNFα, and 
chemokines CCL2 was greatly diminished in silenced cells, compared to the 
controls (Figure 20). These data show that viral RNA was able to activate an 
innate immune response that promoted an inflammatory response associated 
with TMEV-IDD.  
The viral RNA in microglia exosomes can be transferred to infiltrating 
immune cells 
TMEV establish a life-long infection in susceptible mice, particularly in 
microglia. Exosomes secreted by infected microglia contain viral RNA could be 
detected starting from day one post infection. Infiltrating immune cells including 
dendritic cells, monocytes, and macrophages can be detected within the first few 
days after the infection and continues through persistent disease, although at a 
lower level. We wanted to determine whether the infiltrating immune cells also 
take up the microglia exosomes containing viral RNA secreted during chronic 
TMEV-IDD. Microglia exosomes from TMEV-IDD mice brains and spinal cords 
were isolated as previously described and placed on cultures of dendritic cells, 
monocytes, and macrophages. After 24 hours of incubation, real time PCR was 
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able to identify viral RNA in dendritic cells (Figure 21A), monocytes (Figure 21B), 
and macrophages (Figure 21C). These data were particularly intriguing because 
they suggest that exosomes could transfer viral RNA to not only the local cells 
but also the immune cells that enter from the periphery. 
Exosomes secreted by microglia during TMEV-IDD activate an innate 
immune response in infiltrating immune cells 
 Innate immune cell such as dendritic cells and monocytes/macrophages 
are sources of pro-inflammatory cytokines and chemokines following viral 
infection. These cells usually infiltrate into the CNS following viral infection and 
injury. The magnitude of inflammation seen in the CNS during TMEV-IDD 
suggests that infiltrating cells may also partake in substantiating the inflammation 
in the CNS during the chronic TMEV-IDD. Thus, we wanted to know whether 
microglia exosomes from the TMEV-IDD mice brains and spinal cords could 
activate the infiltrating cells. Microglia exosomes were added to uninfected 
dendritic cells, monocytes, and macrophages to determine if an immune 
response could be provoked. After 24 hours of incubation, cells were lysed. Real-
time PCR analysis showed that type I IFNs, IFNα and IFNβ, pro-inflammatory 
cytokines, IL-1β, IL-6, IL-12, TNFα, and chemokines CCL2 were greatly 
increased in the dendritic cells (Figure 22A-E), monocytes (Figure 22F-J), and 
macrophages (Figure 22K-O) incubated with microglia exosomes from TMEV-
IDD mice compared to the cells received naïve microglia exosomes. These data 
reveal that microglia exosomes could be mediating the inflammatory response in 
not only CNS-resident cells but also infiltrating immune cells during TMEV-IDD. 
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Microglia exosomes from mice with chronic TMEV-IDD into naïve mice 
causes neuroinflammation in naïve mice 
            The results from our ex vivo experiments showed that exosomes secreted 
by microglia during TMEV-IDD contain viral RNA that can be transferred to and 
activate an inflammatory response in uninfected bystander cells including 
microglia, astrocytes, neurons, dendritic cells, monocytes, and macrophages. 
The more important question is whether those phenomena could be repeated in 
vivo. Hence, microglia exosomes (500ug) from the TMEV-IDD mice brains or 
spinal cords was injected into the right hemisphere of naïve mice. Two days later, 
mice brains were dissected from mice and dissociated for RNA isolation. Viral 
RNA was detected using real time PCR in the brains of the injected mice (Figure 
23A). Further, the presence of viral RNA in the brains of naïve mice was 
visualized using fluorescent TMEV RNA probe (Figure 23B). Most importantly, 
microglia exosomes from TMEV-IDD mice brains and spinal cords could increase 
the expression of type I IFNs, IFNα and IFNβ, and pro-inflammatory cytokines, 
TNFα, IL-6, IL-1β, and chemokine, CCL2 (Figure 24). Intracerebral injection of 
naïve microglia exosomes into naïve mice did not provoke an immune response. 
Overall, these data show that exosomes released by microglia during TMEV-IDD 









Figure 16. Microglia secrete exosomes during TMEV-IDD in mice express 
activation markers. 
Exosomes were isolated from brains and spinal cords of naïve mice (Naïve Brain 
Exo, Naïve SC Exo) or mice with TMEV-IDD (TMEV Brain Exo, TMEV SC Exo) 
and sorted for microglial CD11b marker using magnetic bead. CD11b+ exosomes 
(microglia exosomes) were fluorescently labeled with antibody for exosomal 
marker CD63 (A-D). Flow cytometry was done on the labeled exosomes for the 
expression of specific markers as shown in the black lines in comparison 
with isotype control antibodies in the gray line. Microglia exosomes 
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(CD11b+CD63+) from naïve brains (red line, E-H), TMEV-IDD brains (black line, 
E-H), naïve spinal cords (red line, I-L), and TMEV-IDD spinal cords (black line, 
I-L) were fluorescently labeled with antibodies for activation markers CD80, 
CD86, MHC class II, and CD40. Flow cytometry was done on the labeled 
exosomes for the expression of specific markers. These are representative 




Figure 17. Exosomes secreted by microglia of mice with TMEV-IDD contain 
viral RNA genome that is transferred to bystander CNS cells. 
Microglia exosomes were isolated from brains and spinal cords TMEV-infected 
mice at 1, 2, 3, 4, 7, 10, 28, 42, 63, and 96 dpi. Viral RNA was assessed by real-
time PCR with TMEV primers (A). Microglia exosomes were isolated from brains 
and spinal cords of naïve mice or mice with TMEV-IDD (63dpi) contained viral 
RNA assessed by real-time PCR with TMEV primers (B) or by conventional PCR 
with primers for long TMEV (5.4kbp) product or for β-actin (C).  In transfer 
experiments, microglia exosomes from mice brains and spinal cords isolated 
during TMEV-IDD were placed on microglia culture. Cells were lysed 24 hours 
later for RNA isolation and cDNA conversion. Real-time PCR was done with 
primers for TMEV (D). Similarly, RNA was assessed for TMEV from astrocytes 
(E) and neurons (F) that were incubated with microglia exosomes. Microglia 
exosomes isolated from brains and spinal cords of naïve mice or mice with 
TMEV-IDD were placed on naïve microglia. After 4 hours, the media containing 
exosomes was removed and replaced with fresh media. After 0 and 20 hours, 
cells were lysed and analyzed by real-time PCR for TMEV (G). Significant 
difference was determined by one-way ANOVA and Bonferroni’s multiple 
comparison test (p<0.001) based on expression by naïve cells.  These are 
representative graphs from one experiment of three individual experiments.  
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Figure 18. Activation of bystander microglia after taking up exosomes 
secreted by microglia during TMEV-IDD.  
Microglia exosomes were isolated from mice brains and spinal cords from naïve 
or TMEV-IDD mice. The isolated exosomes were placed on naïve microglia 
(1x106) for 24 hours. Microglia were lysed, RNA isolated, converted to cDNA. 
Real time PCR was performed to measure the expression of IFNα (A), IFNβ (B), 
IL-1β (C), IL-6 (D), IL-12 (E), TNFα (F), and CCL2 (G). Significant differences 
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were determined by one-way ANOVA and Bonferroni’s multiple comparison test 
(p<0.001) based on expression by naïve microglia. These are representative 
graphs from one experiment of four individual experiments. 
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Figure 19. Activation of bystander astrocytes and neurons after the 
exposure to exosomes secreted by microglia during TMEV-IDD. 
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Microglia exosomes were isolated from naïve or TMEV-IDD mice brains and 
spinal cords. The isolated exosomes were placed on naïve (A-F) astrocytes and 
(G-L) neurons for 24 hours. Cells were lysed for RNA isolation and cDNA 
generation. Real time PCR was performed to measure the expression of IFNα (A 
and G), IFNβ (B and H), IL-1β, (C and I), IL-6 (D and J), TNF-α (E and K), and 
CCL2 (F and L). Significant difference was determined by one-way ANOVA and 
Bonferroni’s multiple comparison test (p<0.001) based on expression by naïve 
astrocytes and neurons. These are representative graphs from one experiment of 
four individual experiments.  
 
Figure 20. Bystander microglia are activated by exosomes from microglia 
isolated during TMEV-IDD via innate immune receptors. 
Microglia were transfected with siRNA for MyD88, MAVS, control siRNA or no 
siRNA control (6 hours). Microglia exosomes were isolated naïve or TMEV-IDD 
mice brains and spinal cords. Exosomes were placed on the transfected 
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microglia for 24 hours. Microglia were lysed, RNA was isolated, and converted 
to cDNA for PCR analysis. The expression of IFNα (A), IFNβ (B), IL-1β (C), IL-6 
(D), TNFα (E), and CCL2 (F) were measured and the significant differences were 
determined by one-way ANOVA and Bonferroni’s multiple comparison test 
(p<0.001) based on control siRNA transfected microglia. These are 
representative graphs from one experiment of three independent repeated 
experiments.   
 
Figure 21. Exosomes from microglia during TMEV-IDD transfer viral RNA to 
infiltrating immune cells.  
Microglia exosomes were isolated from brains and spinal cords of naïve mice or 
mice with TMEV-IDD. Microglia exosomes were placed on dendritic cells (A), 
monocytes (B), and macrophage (C). Cells were lysed 24 hours later for RNA 
isolation and cDNA conversion. Real-time PCR was done with primers for TMEV. 
Significant differences were determined by one-way ANOVA and Bonferroni’s 
multiple comparison test (p<0.001) based on expression by naïve cells.  These 




Figure 22. Exosomes secreted from microglia during TMEV-IDD activate 
infiltrating immune cells to express inflammatory mediators. 
Microglia exosomes were isolated from naïve or TMEV-IDD mice brains and 
spinal cords and placed on naïve (A-E) dendritic cells, monocytes (F-J), and 
macrophages (K-O) for 24 hours. Cells were lysed for RNA isolation and cDNA 
generation. Real time PCR was performed to measure the expression of IFNα (A, 
F, K), IFNβ (B, G, L), IL-6 (C, H, M), TNFα (D, I, N), and CCL2 (E, J, O). 
Significant differences were determined by one-way ANOVA and Bonferroni’s 
multiple comparison test (p<0.001) based on expression by unstimulated 
monocytes and macrophages. These are representative graphs from one 
experiment of three individual experiments.  
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Figure 23. Exosomes secreted by microglia during TMEV-IDD transfer viral 
RNA to naïve mice. Microglia exosomes were isolated from naïve or TMEV-IDD 
mice brains and spinal cords. Exosomes (500μg) were injected intracranially into 
naïve mice. At 2 days post injection, brains were removed from mice (3 
mice/group), and RNA was isolated, converted into cDNA and used in real time 
PCR with primers for TMEV (A). Significant differences were determined by the 
one-way ANOVA and Bonferroni’s multiple comparison test (p<0.001) based on 
the naïve mouse brain. TMEV RNA (green), Iba1 (red), and DAPI (blue) were 
labeled with probe according to RNAScope in situ hybridization technique. 




Figure 24. Exosomes secreted by microglia during TMEV-IDD induce 
neuroinflammation in naïve mice.  
Microglia exosomes were isolated from naïve or TMEV-IDD mice brains and 
spinal cords. Exosomes (500μg) were injected intracranially into naïve mice. At 2 
days post injection, the brains were removed from mice (3 mice/ group), and 
RNA was isolated, converted into cDNA to use in real time PCR. Expression of 
IFNα (A), IFNβ (B), IL-1β (C), IL-6 (D), TNFα (E), and CCL2 (F) were measured. 
Significant differences were determined by the one-way ANOVA and Bonferroni’s 
multiple comparison test (p<0.001). 
DISCUSSION  
           TMEV-IDD has been used as a valuable murine model to study the chronic 
progressive demyelinating phase of MS. This model closely recapitulates the 
hallmarks of disease as it starts with the initial inflammation in the CNS driven by 
viral infection followed by the progressive chronic demyelinating disease 
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associated with neuroinflammation due to persistent viral infection11, 79.  TMEV 
infects and persists in microglia for the lifetime of susceptible mice26. Our 
previous studies showed that exosomes secreted by microglia (microglia 
exosomes) shortly after TMEV infection carry viral RNA and the viral RNA 
genome was transferred to bystander CNS cells including uninfected microglia, 
astrocytes, and neurons. Moreover, the bystander cells express pro-inflammatory 
mediators after being exposed to microglia exosomes containing viral RNA 
(Chapter 2).  
These studies focus on the contribution of microglia exosomes secreted 
during the chronic phase of TMEV-IDD, which has differences from the acute 
phase11. Interestingly, previous studies have shown that the inflammation in the 
CNS, particularly the spinal cord, during the chronic phase is driven by an innate-
like response, not adaptive immune response. This phenomenon might 
contribute to chronic inflammation and development of TMEV-IDD32. Persistent 
viral infection could be the key factor which accounts for the constant 
inflammatory response in the CNS as studies have shown that the administration 
of IFNβ could alleviate the severity and progression in mouse TMEV-IDD and 
human MS41, 80. Similar to the acute phase, in the chronic phase, microglia, 
continue to secret exosomes containing viral RNA and genome that allow for 
transfer of viral RNA to uninfected bystander CNS cells (microglia, astrocytes, 
and neurons) and infiltrating immune cells (dendritic cell, monocytes, and 
macrophages). The transfer is independent of viral particles as shown by the lack 
of viral capsid protein and plaque assay (data not shown). The viral RNA in 
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microglia exosomes were replication competent as the level of viral transcripts 
was amplified over time inside the recipient cells. Most importantly, these 
exosomes could elicit an inflammatory response in bystander cells and naïve 
mice, which was shown to be important in neuroinflammation and the 
development of TMEV-IDD. 
Exosomes package messages including nucleic acids and proteins that 
can be carried from one cell to another81. The external and internal contents of 
exosomes is reflective of the activation stage of their cells of origin; thus, the 
proteomics and transcriptomics of exosomes can be potentially used as 
biomarkers of diseases. We found that microglia in the brains and spinal cords of 
mice during TMEV-IDD secrete exosomes. The exosomes expressed microglial 
marker, CD11b, and exosome markers CD63. The exosomes also expressed a 
high level of MHC class II molecule, costimulatory receptors, CD80 and CD86, 
and activation marker CD40, similar to the activation markers on microglia during 
TMEV-IDD. 
During the acute infection, TMEV can infect several cell types such as 
microglia, monocytes/macrophages, astrocytes, and neurons. However, TMEV 
only persist long-term in microglia26, 82. The mechanism of how TMEV persists is 
not fully understood but most likely is due to inefficient viral clearance in 
susceptible mice. In the chronic demyelinating disease phase, viral RNA 
continues to be detected by sensitive PCR, and low level of infectious viral 
particles can be isolated (data not shown). In the last few years, viruses were 
found to exploit exosomes for their pathogenesis and spread. For examples, 
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exosomes released from enterovirus 71 virus-infected oral mucosal cells are 
enriched in miR-30a that can suppress type I IFNs through inhibiting MyD88 in 
macrophages, thus enabling viral replication83. Viruses such as hepatitis C virus, 
human immunodeficiency virus, and Dengue virus, can utilize vesicular secretion 
mechanism to enhance their replication and spread by loading exosomes with 
viral and host functional protein61, 63, 84. The current studies found that exosomes 
secreted by microglia contain viral RNA throughout TMEV infection. Ten critical 
time points were selected to collect exosomes. Day 1-4, the innate immunity 
becomes detectable. Day 7, virus-specific lymphocytes can be detected. Day 10-
14, virus titers typically decline significantly in susceptible mice. Beyond day 28, 
infected mice enter the chronic infection phase. Day 42, demyelination occurs 
with assessable clinical symptoms. The scope of this chapter is day 63 post 
infection and onward. After day 63, it was observed that infected mice develop 
demyelinating disease with progressive clinical symptoms. These data suggest 
that exosomes could be one of the ways that viruses can persist in the host. 
Due to their cell-derived membrane, exosomes can be taken up by other 
cells to facilitate the content exchange. The microglia exosomes isolated during 
TMEV-IDD could transfer viral RNA to bystander uninfected microglia. The viral 
RNA in the recipient cells was able to replicate, inferring replication had occurred. 
Since there is a crosstalk between cells in the CNS, we wanted to look at 
whether microglia exosomes could be taken up by astrocytes and neurons.  
Microglia exosomes from the brains and spinal cords of mice isolated during 
chronic TMEV-IDD were placed onto astrocytes and neuron. The viral RNA was 
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detected in bystander astrocytes and neurons. Thus, the persistence of TMEV 
viral RNA in the CNS could be facilitated via exosomes.  
TMEV infection can lead to activation of an innate immune response in 
microglia21. Our studies showed that microglia exosomes elicited a pro-
inflammatory response in the bystander microglia including the expression of 
type I IFNs, IFNα and IFNβ, pro-inflammatory cytokines IL-1β, IL-12, IL-6, TNFα, 
and chemokines CCL2. Microglia in spinal cord have been suggested to play a 
critical role in demyelinating disease as they are more reactive than those in the 
brain77. Microglia exosomes isolated from brains and spinal cords did not show 
significant differences in viral RNA level or functionality, as long as the same 
quantity of exosomes was used in the experiments. Silencing viral RNA-sensing 
innate immune receptors signaling, MYD88 and MAVS, decreased the 
expression of the cytokines and chemokines upon the exposure to microglia 
exosomes. These results suggest that bystander cells were activated by viral 
RNA in microglia exosomes secreted during TMEV-IDD. 
The activation status of microglia might have a direct effect on astrocytes 
and neurons, especially in the context of neurodegenerative diseases and 
neurotoxicity. Supernatant from activated microglia alone is sufficient to activate 
astrocytes to release cytotoxic factors that cause dopaminergic neuron death, 
commonly seen in Parkinson’s disease85. In EAE mouse model, the absence of 
aryl hydrocarbon receptor (Ahr) on microglia decreases NF-kB inhibitor, SOCS2 
molecules, and can lead to the enrichment of VEGFB to induce the expression of 
CCL2, NOS2, IL1 β in astrocytes86. In the current studies, microglia exosomes 
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isolated during TMEV-IDD could activate astrocytes and neurons to secrete type 
I IFNs, pro-inflammatory cytokines, and chemokines, possibly contributing to the 
overall inflammatory milieu in the CNS during TMEV-IDD. 
Infiltrating immune cells have been shown play a role in TMEV-IDD 
development67. However, no work has been done on the activities of infiltrating 
dendritic cells, monocytes, and macrophages in TMEV-IDD. In the current 
studies, microglia exosomes from TMEV-IDD could transfer viral RNA to dendritic 
cells, monocytes, and macrophages and activate the cells toward an 
inflammatory response. These results showed that exosomes can serve as 
vehicles to distribute viral RNA to not only CNS cells but also infiltrating immune 
cells.  
Based on the ex vivo data, we wanted to determine if the microglia 
exosomes from the brains and spinal cords of mice during chronic TMEV-IDD 
could have a similar effect in vivo. Thus, microglia exosomes were injected 
directly into the right hemisphere of naïve mice to find that the viral RNA inside 
microglia exosomes was transferred to the naïve brains. Most importantly, 
microglia exosomes could induce inflammatory mediators, type I IFNs, pro-
inflammatory cytokines, and chemokines, in the naïve mice brains, which is the 
hallmark of TMEV-IDD and human MS. Injection of microglia exosomes from 
naïve mice did not induce inflammation in mice. The chosen injection route of 
exosomes was intracerebral, albeit other routes such as intrathecal and 
intravenous injections could have been as effective as long as an effective dose 
was used. 
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In human, disease-modifying therapies (DMTs) have shown to only be 
more effective in relapse-remitting MS but not progressive MS6. Most of the 
available DMT such as natalizumab (blocking the infiltration of immune cells into 
the CNS) or rituximab and ocrelizumab (elimination of B cells) provide little to no 
therapeutic benefit in chronic progressive MS. One explanation is that in chronic 
progressive MS, only CNS resident microglia remain persistently active whereas 
infiltrating cells are no longer present or activated23. Thus, further investigations if 
microglia and the exosomes that microglia secrete, would enhance the 
understanding of the pathogenesis of chronic virus-initiated demyelinating 
disease or human chronic progressive MS. 
MATERIALS AND METHODS 
Mice 
5 to 6-week-old female SJL/J mice and pregnant mice were purchased 
from Envigo (Madison, WI). Neonatal SJL mice were used for primary microglia 
and astrocytes isolation. Mice were housed and handled at University of 
Minnesota Research Animal Resource Center accredited by the American 
Association for Accreditation of Laboratory Animal Care.  
Isolation and culture of cells 
Isolation of primary glial cultures from neonatal mice was performed, as 
previously described21. Briefly, brains were removed from 1 to 3 days old mice, 
and the meninges were removed. The left and right hemispheres of the brain 
were dissociated in a nylon mesh bag. The cells were resuspended in DMEM-
F12 media (Lonza) supplemented with 10% FCS (Invitrogen Life Technologies) 
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and 100U/ml penicillin and 100mg/ml streptomycin (Invitrogen Life 
Technologies). The cells were seeded in poly-D-lysine (Sigma- Aldrich) coated 
tissue culture flasks and incubated at 37°C. After 10-14 days of incubation, 
the microglia were shaken off from the astroglial layer on an orbital shaker for 24 
hours. The primary microglia were removed from the flasks and placed in DMEM 
(Invitrogen Life Technologies) supplemented with 10% exosome-free FCS 
(Invitrogen Life Technologies) and 3ng/ml rGM-CSF (R&D Systems). Microglia 
were seeded in 24-well plates coated with poly-D-lysine. Dorsal root ganglia 
neurons (DRGs) were collected as described87. In summary, DRGs were 
dissected and aspirated in trypsin. The cells were resuspended in Ham’s F12 
media (Invitrogen Life Technologies) supplemented with 2mM L-glutamine, 
10U/ml penicillin, 100U/ml streptomycin, and 0.15mg/ml DNAse I (Sigma) and 
placed in laminin coated flask.  
Bone marrow derived monocytes (monocytes), bone marrow derived 
macrophages (macrophages), and bone marrow derived dendritic cells (dendritic 
cells) were isolated from femurs and tibia of adult mice.  Briefly, both ends of 
femurs and tibias were incised to allow bone marrow cells to be flushed out by 
balanced salt solution (BSS) using a syringe with 27-gauge needle. Cells were 
washed with BSS twice, resuspended, and passed through a cell strainer. Bone 
marrow cells (14× 106 cells per T75 flask) were cultured in complete DMEM with 
3ng/ml of recombinant granulocyte-macrophage colony-stimulating factor (GM-
CSF) (R&D System) for monocyte induction, 10ng/ml of GM-CSF for 
macrophage induction (based on CD11b+CD11C- cells), and 20ng/ml of GM-CSF 
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and 10ng/ml IL-4 for dendritic cell induction88.  On day 4, monocytes were re-
stimulated with GM-CSF and ready for use. On day 7, macrophages were re-
stimulated with GM-CSF and ready for use. For dendritic cells, on day 3, 75% of 
media including non-adherent cells was replaced with fresh dendritic cell media. 
On day 6, the adherent dendritic cells were stripped all using Versene, and 
replated. On day 10, dendritic cells were ready for use88. 
Transfection 
Microglia were transfected with siRNAs specific for MyD88 or 
MAVS, 5mM SMARTpool siRNA (a mixture of 4 siRNAs in one reagent) 
or siCONTROL (Dharmacon) using Dharmafect 4 reagent according to 
manufacture protocol. Silencing was guaranteed by Dharmacon with 75% or 
better efficiency and 90% reduced off-targets.  
TMEV-IDD induction 
SJL female mice were intracranially injected with 2X106 PFU of 
TMEV, BeAn 8386 strain. To detect viral RNA in microglia exosomes throughout 
TMEV infection, we sacrificed mice at 1, 2, 3, 4, 7, 10, 14, 28, 42, 63, and 96dpi 
to collect microglia exosomes from brains and spinal cords.  Mice started to show 
clinical symptoms between 30-40 dpi and advanced into chronic 
progressive demyelinating disease around 63 dpi, akin to human primary 
progressive MS. Clinical symptoms include mild to severe gait abnormalities, 
righting inability, and worst, irreversible paralysis89. Infected mice were 
euthanized at 63 dpi. Brain and spinal cords were collected for microglia 
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exosomes isolation. Microglia exosomes isolated from brain and spinal cords of 
age-matched naïve mice were used as the controls.   
Exosome isolation and analysis 
The brains and spinal cords were dissociated through a metal screen 
(70mM pore) into Hank’s balanced salt solution. The homogenates were first 
centrifuged at 2,000xG for 10 minutes and then increased to 4,200xG 
for another 45 minutes to remove cells and debris. The total exosomes were 
isolated from the clear homogenates with the Total Exosome Isolation reagent 
(Invitrogen). To select for exosomes from microglia, total exosomes were 
then incubated with antibody for CD11b (microglia marker) conjugated to 
magnetic beads and sorted on a column per manufacturer protocol (Miltenyi). 
CD11b+ exosomes (microglia exosomes) were then ready for further 
application. Pierce BCA protein assay (Thermo Fisher Scientific) was used 
to determine concentration of exosomes. Additional protein analysis was 
conducted using mass spectrometry using 120mg protein separated on 4-
12% Bis-Tris gels (Invitrogen). Cysteine bonds were reduced and alkylated with 
10nM DTT in 50mM ammonium bicarbonate and 55mM iodoacetamide: 
50mM NH4HCO3. Proteins were digested in 50mM NH4HCO3, 5mM 
CaCl2, 5ng/ml trypsin. The samples were eluted with acetonitrile: H2O (6:4), 
0.1% trifluoroacetic acid before analysis on Thermo Orbitrap Elite mass 
spectrometer at the University of Minnesota Center for Mass Spectrometry. 
100mg or 500mg of isolated microglia exosomes were added to 1x106 cultured 
cells or injected intracranially into mice, respectively. RNAScope RNA in 
 91 
situ hybridization (ACD) was used to visualize TMEV RNA in cells or tissues. 
Images were captured with an Olympus BX51 confocal microscope at 10x and 
20x magnification.  
RNA isolation and PCR analysis 
RNA was extracted from microglia exosomes using the Total Exosome 
RNA and protein isolation kit (Invitrogen). RNA was isolated from microglia, 
astrocytes, and neurons using SV Total RNA Isolation kit which contains 
a DNAse reaction (Promega). RNA was isolated from brain tissue using 
Trizol protocol followed by DNAse digestion (Thermo Fisher Scientific). First 
strand cDNA was made from 1μg of total RNA using oligo(dT)12-18 primers and 
Advantage for RT-PCR kit in a final volume of 100μl (Clontech). Real-time PCR 
was conducted in triplicate with Rotor-Gene SYBR green RT-PCR kit (Qiagen). 
Briefly, 0,5mM primers, 1X SYBR Green reagent, and 2μl of cDNA were 
combined in 10μl reactions. The primers for TMEV, IFNs, cytokines, and 
chemokines were previously described20, 21. Rotor-Gene Qiagen Q real time PCR 
was conducted using hot start with 40 cycles of  95°C for 15s; 60°C for 20s; 72°C 
for 15s, followed by a melt from 75°C to 95°C. Quantitation of the mRNA was 
based on standard curves derived from cDNA standards for each primer pair. 
Positive and negative cDNA controls were used for each primer pair using cells 
known to express or not express the specific mRNA. Samples from different 
groups were normalized based on expression of ß-actin. All samples were run in 
triplicate for each primer pair. Statistical analysis comparison between groups 
was determined by one-way analysis of variance (ANOVA) and Bonferroni’s 
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multiple comparison test (p<0.001). PCR for viral genomes was conducted using 
cDNA in 25μl reactions with TMEV primers (0.5mM), dNTPs (200mM), 1X 
reaction buffer, and Q5 high fidelity DNA polymerase (0.02U/ml) (New 
England BioLabs) on Eppendorf Mastercycler with a hot start and 40 cycles: 
95°C for 30s; 60°C for 30s; 72°C for 8 minutes, followed by a 20-minute 
extension. PCR products were separated on 0.8% agarose gel with Sybr Safe 
(Thermo Fisher Scientific) and imaged.  
Flow Cytometry 
Exosomes were isolated from both TMEV infected brains and spinal cords 
as described earlier. Exosomes were then incubated with latex beads 
(Invitrogen) for 2.5 hr at RT per the manufacturer protocol. Glycine was added to 
the mixture and then washed with PBS. Exosomes/beads were incubated for 45 
minutes at 4°C with FITC-conjugated Abs specific for CD45, CD11b or CD4, PE 
conjugated Abs specific for CD63, I-As (MHC class II), CD86, CD80, and CD40 
(BD). Following Ab binding, exosome/beads were washed and then fluorescence 
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BACKGROUND 
Monocytes are derived in the bone marrow and can differentiate into a 
wide spectrum of activation states, ranging from activated macrophages with 
inflammatory properties to immunosuppressive subsets, such as suppressive 
monocytes and myeloid-derived suppressor cells (MDSCs).  Suppressor subsets 
strongly expand during tumor growth and play an important role in cancer 
evasion of the immune response.  The presence of suppressor subsets in 
patients is associated with cancer progression, metastasis, and reduced 
response to therapy90, 91.  Suppressive monocytes can regulate the function of 
other immune cell types, including T cells, dendritic cells, macrophages, and 
natural killer cells. The mechanisms by which monocytes acquire suppressive 
activity remains poorly defined, and it is uncertain whether suppressive 
monocytes represent a distinct myeloid lineage or a group of immature myeloid 
cell types with halted differentiation. Nonetheless, accumulation of suppressive 
monocytes inhibits antitumor immune responses necessary for controlling tumor 
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growth and metastasis92.  In humans, CD33+CD11b+CD14+HLA-DRlo/neg cells 
which are monocytes with low to no expression of MHC class II have been 
shown to be increased in several different types of cancer, including melanoma, 
glioblastoma, and renal cell carcinoma93-95.  The CD14+HLA-DRlo/neg monocytes 
have been shown to be immunosuppressive and increased numbers of these 
cells correlate with poor patient outcomes.  Despite the known importance of 
suppressive monocytes in cancer progression, the mechanisms responsible for 
their generation remain unclear.  
Tumors secrete a wide range of cytokines and metabolites that may 
directly promote the differentiation of suppressive monocytes.  Tumors can 
secrete granulocyte-macrophage colony-stimulating factor (GM-CSF), 
prostaglandin E2 and TGFb that are capable of reaching the bone marrow and 
contributing to monocyte differentiation94, 96.  Previous studies have shown that in 
vitro culture medium from tumor cells, glioma and renal cell carcinoma, contain 
factors that can promote differentiation of suppressive monocytes97, 98.  Additional 
studies have demonstrated that suppressive monocytes can be differentiated 
from murine bone marrow when cultured in medium collected from cancer cell 
lines and supplemented with GM-CSF and IL-499, 100.  Thus, factors secreted by 
tumor cells have the ability to promote differentiation of suppressive monocytes. 
Extracellular vesicles (EVs) are small membrane-bound vesicles released 
from cells and taken up by other cells as a means of intercellular communication.  
EVs contain proteins, mRNA, miRNA, and lipids that can then be transferred to 
another cell70.  EVs play an important role in maintaining homeostasis under 
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healthy conditions. However, during disease states, EVs may transport contents 
that negatively impact surrounding cells.  Tumor cells release EVs at a markedly 
increased rate compared to normal cell types101, 102.  Tumor-derived EVs have 
been shown to regulate T cell function by mediating the apoptosis of cytotoxic T 
cells and promoting the expansion of T regulatory cells103-105.  Tumor derived 
EVs have also been shown to reduce the cytotoxic activity of natural killer 
cells103-105.   
In the current study, we examined whether tumor derived EVs can affect 
monocyte differentiation. These studies show that EVs secreted by tumor cells 
can be taken up by bone marrow derived monocytes and promote the 
differentiation of monocytes toward a suppressive phenotype. Monocytes 
exposed to tumor derived EVs have reduced expression of MHC class II and 
costimulatory molecules as well increased expression of PD-L1. Most 
importantly, monocytes exposed to tumor derived EVs had reduced ability to 
activated antigen specific CD4+ T cell responses compared to monocytes 
exposed to EVs from non-malignant cells.  These studies were conducted with 
tumor cells from a variety of tumor types to demonstrate that EVs are a common 
mechanism used by tumors for promoting suppressive monocytes.  These 
findings suggest that tumors secrete EVs to promote an immunosuppressive 
microenvironment.  
RESULTS 
EVs secreted by tumor cells promote bone marrow derived monocytes to 
express suppressive cytokines and effector molecules 
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 Monocytes that infiltrate into areas of tumor have been shown to have 
suppressive features and are often referred to myeloid- derived suppressor cells 
(MDSCs).  Tumors may promote the generation of MDSCs through secreted 
products.  Thus, we wanted to determine whether EVs secreted by tumor cells 
may promote the suppressive properties of monocytes.  EVs were isolated from 
various types of tumor cells lines, including osteosarcoma (K12), glioma (GL261), 
colon carcinoma (CT26), sarcoma (NCTC), and melanoma (B16OVA).  As 
controls for the tumor cells, EVs were isolated from primary cultured cells of the 
cell types from which the tumor cells were derived.  The isolated EVs were 
confirmed for size by Nanosight analysis and expression of EVs markers, 
including CD63, by flow cytometry and confirmed by western blot for all EVs 
(Figure 25J-M, shows glia and GL261).  The EVs were labeled with florescent 
dye and added to bone marrow derived monocytes to determine whether the 
monocytes were able to take up the EVs secreted by tumor cells (Figure 25A-I).  
The monocytes were able to take up EVs secreted from the tumor cells as well 
as the primary cell controls for all the different types of cells. 
 Next, we wanted to determine whether EVs secreted by tumor cells could 
alter the activation of monocytes.  EVs were isolated from tumor cells and 
primary cells, and the EVs were added to bone marrow derived monocytes for 4 
days.  After 4 days, the monocytes were analyzed for expression of cytokines 
and effector molecules by real time PCR (Figure 26 and 27).  EVs secreted by 
osteosarcoma (K12) cells decreased the expression of pro-inflammatory 
cytokines IL-12 and TNFα and increased the expression of suppressive cytokine 
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IL-10 and TGFβ as well as suppressive molecules, arginase and inducible nitric 
oxide synthase (iNOS), by bone marrow derived monocytes as compared to EVs 
secreted by osteoblast cells (Figure 26).  The glioma cells (GL261) were grown in 
stem cell as well as differentiated state to represent the different stages in 
tumors.  The EVs secreted by glioma cells (GL261S and GL261D) decreased the 
expression of pro-inflammatory cytokines, IL-12 and TNFα and increased the 
expression of suppressive cytokines, IL-10 and TGFβ as well as suppressive 
molecules, arginase, and iNOS, by monocytes as compared to EVs secreted by 
glia cells (Figure 26).  EVs secreted by colon carcinoma (CT26) and sarcoma 
(NCTC) cells decreased the expression of pro-inflammatory cytokines, IL-12 and 
TNFα and increased the expression of suppressive cytokines, IL-10, and TGFβ 
as well as suppressive molecules, arginase and iNOS, by bone marrow derived 
monocytes as compared to EVs secreted by fibroblast (Figure 27).  EVs secreted 
by melanoma cells (B16OVA) decreased the expression of pro-inflammatory 
cytokines, IL-12 and TNFα and increased the expression of suppressive 
cytokines, IL-10 and TGFβ as well as suppressive molecules, arginase and 
iNOS, by monocytes as compared to EVs secreted by melanocytes (Figure 27).  
These results show that EVs secreted by various types of tumor cells decreases 
the expression of pro-inflammatory cytokines by monocytes and promotes the 
expression of suppressive cytokines and effector molecules by monocytes. 
 A recent study showed that media from GL261 glioma cells reduced the 
pro-inflammatory cytokines expressed by bone marrow derived monocytes via 
suppressor of cytokines 3 (SOCS3) dependent mechanism.  SOCS3 is a 
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negative regulator of the Janus Kinase (JAK)/Signal Transducer and Activator of 
Transcription (STAT) and NFkB signaling pathways which promote expression of 
pro-inflammatory cytokines106, 107.  Therefore, we wanted to determine whether 
EVs isolated from GL261 glioma cells as well as from other tumor cells 
upregulated SOCS3 expression.  EVs were isolated from tumor cell lines and 
primary cells, the EVs were placed on bone marrow derived monocytes for 4 
days as described above.  After 4 days, the monocytes were analyzed by real 
time PCR for SOCS3 expression (Figure 28).  EVs secreted by osteosarcoma, 
glioma, colon carcinoma, sarcoma, and melanoma increased the expression of 
SOCS3 in monocytes.  Meanwhile, monocytes exposed to EVs secreted by 
corresponding primary cells did not change the expression of SOCS3.  These 
results show that EVs secreted by several different types of tumor cells promote 
the upregulation of SOCS3 in monocytes which reduces the expression of pro-
inflammatory cytokines. 
EVs secreted by tumor cells alter the cell surface markers on monocytes 
 Previous studies have shown that monocytes that infiltrate into the tumor 
microenvironment have reduced expression of MHC class II and co-stimulatory 
molecules and can have increased expression of inhibitory molecules, such as 
PD-L1.  Thus, we wanted to determine whether EVs secreted by tumor cells can 
alter the cell surface markers on monocytes.  EVs secreted by the tumor cells 
were isolated and placed on bone marrow derived monocytes.  After 4 days, the 
monocytes were washed and labeled with fluorescently labeled antibodies for 
CD11b and Ly6C, CD80, MHC class II, and PD-L1. The monocytes were 
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analyzed by flow cytometry to determine expression levels on the surface of the 
cells (Figure 29 and Table 2).  Monocytes exposed to EVs secreted by tumor 
cells, including osteosarcoma, glioma, sarcoma, colon carcinoma, and 
melanoma, had decreased expression of MHC class II as well as co-stimulatory 
molecule, CD80, as compared to monocytes that were exposed to EVs secreted 
by primary cells, including osteoblast, glia, fibroblast, and melanocytes.  Further, 
monocytes exposed to EVs from tumor cells had increased expression of PD-L1 
as well as Ly6C as compared to monocytes exposed to EVs from primary cells.  
These results show that EVs secreted by tumor cells promote monocytes to 
increase Ly6C and PD-L1 and to decrease MHC class II and co-stimulatory 
molecules on their cell surface. 
EVs secreted by tumor cells promote generation of monocytes that 
suppress CD4+ T cells 
 Previous studies have shown that monocytes that infiltrate into tumor 
areas can suppress activated T cells.  Several mechanisms have been proposed 
for suppression of T cells by monocytes including increased secretion of 
suppressive cytokines and negative immune mediators as well as decreased 
expression of MHC class II and co-stimulatory molecules.  Based on our flow 
cytometry data, monocytes exposed to EVs from tumor cells decreased the 
expression of MHC class II and co-stimulatory molecules as well upregulated the 
expression of inhibitory molecule PD-L1 on the cell surface.  Based on our 
cytokine data, monocytes exposed to EVs from tumor cells increased the 
expression of suppressive cytokines and immune mediators, including IL-10, 
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TGFβ, arginase, and iNOS.  Thus, we wanted to determine whether EVs 
secreted by tumor cells promote the generation of monocytes that suppress 
activated CD4+ T cells.  Antigen- specific CD4+ T cells were activated against a 
known mouse virus epitope in C57BL6 mice, TMEV VP421-40.  EVs were isolated 
from tumor cells, including osteosarcoma, glioma, colon carcinoma, sarcoma, 
and melanoma, and from primary cell controls, osteoblast, glia, fibroblast, and 
melanocytes.  The EVs were placed on bone marrow derived monocytes 
continually for 4 days.  After 4 days, the monocytes were removed and placed in 
culture with the activated VP421-40- specific CD4+ T cells in a T cell proliferation 
assay with or without peptide.  The CD4+ T cells were analyzed by flow cytometry 
for CFSE levels indicating proliferation (Figure 30A-M).  When monocytes were 
added that had been incubated with EVs from primary cell cultures, the VP421-40 
specific CD4+ T cells proliferated similar to VP421-40 specific CD4+ T cells that had 
monocytes incubated with no EVs added to the culture.  Most interesting, VP421-
40 specific CD4+ T cells that were incubated with monocytes that were exposed to 
EVs from the tumor cells had greatly reduced proliferation compared to VP421-40 
specific CD4+ T cells that had monocytes incubated with no EVs added to the 
culture.  Similarly, VP421-40 specific CD4+ T cells secreted less IL-2 when 
incubated with monocytes that were exposed to EVs from tumor cells compared 
to monocytes exposed to EVs from primary cells or monocytes with no EVs 
(Figure 30N-O).  These results show that tumor cells secrete EVs that convert 






Figure 25. EVs secreted by tumor cells can be taken up by monocytes.   
EVs were isolated from tumor cells GL261 (A), NCTC (C), CT26 (D), K12 (F), 
B16 (H) and control glia (B), fibroblast (E), osteoblast (G), and melanocytes (I) 
and labeled with CFSE (green).  The EVs were placed on bone marrow derived 
monocytes for 2 hours, and the monocytes were labeled with antibody for CD11b 
(red). DAPI (blue) stained cellular nuclei.  The cells were imaged on a confocal 
microscope, scale bar= 10μm.  EVs were isolated and incubated with 
fluorescently labeled antibody for CD63 and analyzed by flow cytometry (black 
line) compared to isotype control (gray) shown for glia (J) and GL261 (K).  EVs 
















































and GL261 (M).  These are representative images from one experiment of four 
independent repeated experiments.  
Figure 26. EVs secreted by glioma and osteosarcoma tumor cells promote 
the expression of suppressive cytokines and effector molecules by 
monocytes.   
EVs were isolated from osteoblast (osteo), K12, mixed glia, GL261 stem cell 
(GL261S), GL261 differentiated (GL261D) cells.  The EVs were placed on bone 
marrow- derived monocytes for 4 days, and the cells were lysed.  The RNA was 
isolated from lysates, converted to cDNA and used in real time PCR with primers 
for IL-12 (A), IL-10 (B), TNFα (C), iNOS (D), arginase (E), and TGFβ (F). 
Significant difference was determined by the one-way ANOVA and Bonferroni’s 
multiple comparison test (p<0.001) based on bone marrow derived monocytes 
without EVs added. These are representative graphs from one experiment of five 


















Figure 27.  EVs secreted by colon carcinoma, sarcoma, and melanoma 
tumor cells promote expression of suppressive cytokines and effector 
molecules by monocytes.   
EVs were isolated from fibroblast (Fb), CT26, NCTC 2472, melanocytes (Mel), 
and B16OVA cell lines.  The EVs were placed on bone marrow- derived 
monocytes for 4 days, after which the cells were lysed.  The RNA was isolated 
from lysates, converted to cDNA and used in real time PCR with primers for IL-12 
(A), IL-10 (B), TNFα (C), iNOS (D), arginase (E), and TGFβ (F). Significant 
difference was determined by the one-way ANOVA and Bonferroni’s multiple 
comparison test (p<0.001) based on bone marrow derived monocytes without 
EVs added. These are representative graphs from one experiment of five 



















Figure 28.  EVs secreted by tumor cells promote the upregulation of SOCS3 
in monocytes.   
EVs were isolated from osteoblast (osteo), K12, mixed glia, GL261 stem cell 
(GL261S), GL261 differentiated (GL261D) cells (A).  EVs were isolated from 
fibroblast (Fb), CT26, NCTC 2472, melanocytes (Mel), and B16OVA cell lines 
(B).  The EVs were placed on bone marrow-derived monocytes for 4 days.  The 
monocytes were lysed, RNA isolated and converted to cDNA and used in real 
time PCR with primers for SOCS3.  Significant difference was determined by the 
one-way ANOVA and Bonferroni’s multiple comparison test (p<0.001) based on 
bone marrow derived monocytes without EVs added. These are representative 








Figure 29.  EVs secreted by tumor cells alter the surface markers on 
monocytes.   
EVs were isolated from osteoblast (A, K), K12 (B, L), mixed glia (C, M), GL261 
stem cells (D, N), GL261 differentiated cells (E, O), fibroblast (F, P), CT26 (G, Q), 
NCTC (H, R), melanocytes (I, S), and B16OVA (J, T) cell lines.  The EVs were 
placed on bone marrow derived monocytes for 4 days.  The monocytes were 
then incubated with fluorescently labeled antibody for CD11b and PD-L1 (A-J) or 
MHC class II (K-T).  The monocytes were gated on CD11b+ cells.  Histogram 
plots show monocytes without EVs in the black lines and the monocytes with the 
EVs as listed above in the gray line. These are representative plots from one 
experiment of four independent repeated experiments. 
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Figure 30. EVs secreted by tumor cells promote the generation of 
monocytes that suppress CD4+ T cell responses.   
EVs were isolated from osteoblast (B), K12 (C), melanocytes (D), B16OVA (E), 
mixed glia (F), GL261 stem cells (G), GL261 differentiated cells (H), fibroblast (I), 
CT26 (J), NCTC (K) cell lines.  The EVs were placed on bone marrow derived 
monocytes for 4 days.  The monocytes were then washed and cultured with 
CFSE labeled VP421-40 -specific CD4+ T cells with or without VP421-40 peptide.  
After 4 days in culture, the CD4+ T cells were analyzed by flow cytometry for 
Figure 6
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CFSE shown in the histogram plots (A-K) with the black line showing VP21-40- 
specific CD4+ T cells without peptide added and gray line showing with VP21-10 
peptide added.  All groups were conducted in triplicate with one representative 
plot shown for each group.  Results from triplicates are shown in graphs (L and 
M).  Significant difference was determined by the one-way ANOVA and 
Bonferroni’s multiple comparison test (p<0.001) based on bone marrow derived 
monocytes without EVs added.  These are representative plots and graphs from 
one experiment of four independent repeated experiments. 
Table 2: Exosomes from tumor cells alter the surface markers on 
monocytes. Monocytes were exposed to EVs secreted by tumor cells, including 
osteosarcoma, glioma, sarcoma, colon carcinoma, and melanoma for 4 days. 
Monocytes were analyzed by flow cytometry to determine expression level of 
Ly6C, CD80, MHC II, PDL-1 on the surface of the cells.   
DISCUSSION 
Tumor growth and metastasis is dependent on the interaction between 
transformed tumor cells, the tumor microenvironment, and the host immune 
response108. Tumor cells evade detection by the host immune response by 
secretion of soluble factors to promote an immunosuppressive tumor 
microenvironment.  Immunosuppression of monocytes, T cells, and NK cells 
Osteo K12 Glia GL261S GL261D Fibro CT26 NCTC Melano B16
Ly6C  +  ++  +  +++  +++  +  +++  +++  +  +++
CD80  ++  +  ++  +  +  ++  +  +  ++  +
MHC II  ++  +  ++  +  +  ++  +  +  ++  +
PDL-1  +  ++  +  ++  ++  +  ++  ++  +  ++
Table I
Table I.  Exosomes from tumor cells alter the surface markers on monocytes.
Low expression +, medium expression ++, high expression +++
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enables tumor growth.  Circulating monocytes traffic to the site of tumor cell 
growth, however, in the tumor microenvironment, the monocytes then 
differentiate into suppressive monocytes and myeloid-derived suppressor cells 
(MDSCs).  The mechanism by which tumor cells promote the differentiation of 
suppressive monocytes has not been determined, however, previous studies 
have suggested that tumor cells secrete factors that promote the differentiation of 
suppressive monocytes.  In these studies, we wanted to determine whether EVs 
secreted by tumor cells can promote the differentiation of suppressive 
monocytes.  Since several cancers have been associated with differentiation of 
suppressive monocytes, we investigated the contribution of tumor secreted EVs 
by a wide range of solid tumor cell types including osteosarcoma, glioma, colon 
carcinoma, sarcoma, and melanoma.  These studies show that tumor secreted 
EVs can be taken up by bone marrow-derived monocytes.  The monocytes 
exposed to tumor secreted EVs increased the expression of anti-inflammatory 
cytokines and mediators, IL-10, TGFβ, arginase, and iNOS, while decreasing the 
expression of pro-inflammatory cytokines and mediators, IL-12 and TNFα.   The 
tumor secreted EVs also decreased the expression of MHC class II and co-
stimulatory molecules on the monocytes while increasing the expression of PDL-
1.  Finally, monocytes exposed to tumor secreted EVs suppressed activated 
CD4+ T cells.  These results show that tumors secrete EVs that promote the 
differentiation of a suppressive phenotype in monocytes similar to suppressive 
monocytes that accumulate in cancer patients.  Increased numbers of 
suppressive monocytes have been correlated with tumor growth, resistance to 
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chemotherapy, and increased risk of metastasis for a variety of different tumor 
types, including those chosen in the present study: osteosarcoma109, 110, glioma97, 
111-115, colon carcinoma116-118, fibrosarcoma119, and melanoma120, 121.  
Recently EVs have been determined to play an important role in disease 
prognosis and pathogenesis, especially in cancer122, 123.  EVs are a 
heterogeneous population of nano to micro-sized, membranous vesicles that are 
constitutively released by cells.  EVs can be categorized by their biogenesis and 
size.  Exosomes typically range from 30-150nm in diameter and are formed by 
the invagination of endosomes and subsequently released into the 
microenvironment by fusing with cell membrane.  Microvesicles are typically 
bigger, 50-1000nm in diameter, and released by direct budding of cell 
membrane124.  Large oncosomes represent an additional population of EVs 
characterized by their unusually large size (1-10um) and are released by cancer 
cells125.  EVs express surface markers and carry a wide range of materials, 
including proteins, lipids, and genetic materials such as mRNA and miRNA, that 
are specific to their parental cell of origin58.  Tetraspanins, such as CD63, CD9, 
and CD81, are enriched in EVs relative to their cell of origin.  In this study, EVs 
were from a wide range of murine tumor cell lines, including osteosarcoma, 
glioma, colon carcinoma, fibrosarcoma, and melanoma, as well as EVs from 
correspondent control primary non-malignant cells. The EVs isolated from the 
tumor cells and normal cells expressed CD63 and ranged in size from 100-
150nm, suggesting these EVs may be exosomes.  When fluorescently labeled 
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tumor secreted EVs were added to monocytes, the EVs were observed in the cell 
cytoplasm of the monocytes, suggesting active internalization.  
Monocytes are generated in the bone marrow from hematopoietic stem 
cells and then circulate in the blood. During times of inflammation, monocytes are 
recruited into tissue where they differentiate into macrophages.  Macrophage 
express MHC class II and co-stimulatory molecules enabling them to function as 
antigen-presenting cells for CD4+ T cells.  Macrophage also secrete pro-
inflammatory cytokines, such as IL-12 and TNFa, thus supporting both innate 
and adaptive immune responses.  Pro-inflammatory cytokines have anti-tumor 
effects and have been administered to cancer patients in clinical trials with 
relative success126-128.  In contrast, monocytes in the presence of tumors can 
promote the accumulation of immunosuppressive cell subsets, such as tumor-
associated macrophages (TAMs) and myeloid derived suppressor cells 
(MDSCs)129.  In the current studies, monocytes were exposed to EVs secreted by 
tumor cell lines that promoted the development of a suppressive phenotype by 
increasing the expression of anti-inflammatory mediators, IL-10, iNOS, arginase, 
and TGFβ, while decreasing the expression of pro-inflammatory cytokines, IL-12 
and TNFa.  TGFβ and IL-10 promote immune evasion by inducing T cell 
tolerance to tumor peptides and contributing to the generation of regulatory T 
cells29.  TGFβ and IL-10 also downregulate the expression of MHC class II on 
monocytes converting them to suppressive monocytes130, 131.  Notably, EVs 
isolated from the primary, non-malignant control cells did not promote the 
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monocytes to secrete anti-inflammatory cytokines and instead maintained the 
level of pro-inflammatory cytokine expression. 
Several mechanisms may promote the differentiation of monocytes to 
suppressive monocytes by tumor derived EVs.  The JAK/STAT pathway plays a 
key role in transcriptional control of cytokines.   Activation of JAKs leads to 
phosphorylation of STAT transcription factors which promote the expression of 
immune molecules, including interferons and GM-CSF.   JAK/STAT pathway is 
critical in the initiation of innate immunity and myeloid cell development132, 133.  
Suppressor of cytokine signaling 3 (SOCS3) is a negative regulator of the 
JAK/STAT pathway.  IL-10 has been shown to increase the expression of 
SOCS3.  SOCS3 targets JAKs for degradation via proteosomal degradation thus 
inhibiting STAT3 activation106.  SOCS3 has also been determined to inhibit 
signaling in the NFkB pathway and enhancing signaling through the MAPK 
pathway107, 134. Macrophage derived from SOC3 deficient mice display enhanced 
expression of pro-inflammatory cytokines.  The deletion of SOCS3 in myeloid 
cells delays tumor growth and increases survival of mice bearing orthotopic 
glioma tumors135.  In these studies, monocytes exposed to EVs secreted by 
tumor cells had decreased expression of pro-inflammatory cytokines and 
increased expression of IL-10 compared to monocytes exposed to EVs secreted 
by non-malignant cells.  Therefore, we wanted to determine whether SOCS3 
which has been previously shown to be increased by IL-10 would be increased in 
monocytes that took up EVs secreted by tumor cells.  The current studies show 
that monocytes exposed to EVs secreted by tumor cells had increased 
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expression of SOCS3 compared to monocytes exposed to EVs secreted by non-
malignant cell controls.  Thus, SOCS3 regulation may be one mechanism by 
which EVs secreted by tumors contribute to differentiation of suppressive 
monocytes.  
Suppressive monocytes that arise during cancer have been shown to 
have decreased expression of MHC class II, and some have increased 
expression of PD-L1.  The PD-1 receptor is expressed on nearly all immune cell 
types and, upon binding of PD-L1 ligand, results in decreased activity of the 
immune cells.  Tumor cells have been shown to express PD-L1, and high levels 
of PD-L1 have been associated with poor patient prognoses119, 136, 137.  
Checkpoint inhibitors in the form of monoclonal antibodies that bind to PD-1/PD-
L1 reinvigorate exhausted T cells and have resulted in remarkable responses for 
particular tumor types138.  MDSCs characterized as monocytic suppressive cells 
express CD11b and have increased levels of Ly6C expression.  In the current 
studies, monocytes exposed to EVs secreted by tumor cells lead to decreased 
expression of MHC class II and co-stimulatory molecules, CD80, and increased 
expression of PD-L1 and Ly6C on their cell.  Monocytes exposed to EVs from 
non-malignant cells had no change in expression of MHC class II and 
costimulatory molecules and did not express PD-L1 on their surface.  Thus, 
monocytes exposed to EVs from tumor cells would have reduced ability to 
present antigens to CD4+ T cells and may promote tolerance and anergy in the 
CD4+ T cells. 
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Although MDSCs are capable of suppressing a diverse repertoire of 
immune cells, they are most recognized for their potent ability to inactivate both 
CD4+ and CD8+ T cells139, 140.  Mechanisms involved in MDSC-mediated 
immunosuppression of T cells include: elimination of key nutritional factors for T 
cells in the microenvironment via arginase 1 secretion, downregulation or 
desensitization of the T cell receptor and induction of T cell anergy through the 
production of reactive oxygen species (ROS) and inducible nitric oxide synthase 
(iNOS), secretion of immunosuppressive cytokines (IL-10, TGFβ), induction and 
recruitment of Tregs, and upregulation of inhibitory PDL1 on the MDSC surface .   
The results from the current studies showed that monocytes exposed to EVs 
secreted by tumor cells increased the expression of IL-10, TGFβ, iNOS, and 
arginase.  The current studies further showed that monocytes exposed to EVs 
secreted by tumor cell had decreased expression of MHC class II and 
costimulatory concomitant with increased expression of PD-L1.  Thus, we wanted 
to determine whether these monocytes could suppress activated CD4+ Tells.  
Most significantly, the results from the current studies showed that monocytes 
exposed to EVs secreted by tumor cells decreased the proliferation of activated 
CD4+ T cells compared to monocytes exposed to EVs from non-malignant cells.  
Thus, monocytes exposed to EVs secreted by tumor cells had decreased 
expression of MHC class II and increased expression of PD-L1 as well as 
increased expression of suppressive cytokines and effector mediators which 
contributed to the reduced activation and proliferation of antigen-specific CD4+ T 
cells. 
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The current studies show that EVs secreted a variety of tumor cell types 
promote the differentiation of suppressive monocytes and may be a common 
mechanism used by tumors to create an immunosuppressive microenvironment.  
Future studies will characterize and compare the contents of EVs secreted by 
tumor cells to EVs that originate from non-malignant controls to identify specific 
proteins, mRNA, or miRNA that mediate the differentiation of suppressive 
monocytes.  A better mechanistic understanding of how EVs secreted by tumors 
alter monocyte differentiation is critical in the discovery of novel therapeutic 
targets in cancer treatment to reduce immunosuppression and promote immune- 
based removal of cancer.   
MATERIALS AND METHODS 
Mice  
Female 6-7 week old C57BL/6 mice were purchased from Jackson 
Laboratories and maintained in the Research Animal Resource (RAR) facility of 
the University of Minnesota.  All mouse experiences were performed in 
compliance with RAR and Institutional Animal Care and Use Committee (IACUC) 
guidelines.  
Tumor cell lines and primary cell cultures 
Immortalized tumor cell lines osteosarcoma (K12), glioma (GL261), 
melanoma (B16OVA), and colonic carcinoma (CT26) were obtained from the 
National Cancer Institute.  Fibrosarcoma (NCTC 2472) was provided by Dr. 
Donald Simone (University of Minnesota).   Mouse osteosarcoma (K12), glioma 
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(GL261), melanoma (B16OVA), and colonic carcinoma (CT26) cell lines were 
cultured in Dulbecco’s modified Eagle medium (DMEM, Sigma), supplemented 
with 10% EVs-free fetal bovine serum (FBS, Gibco), 100 U/ml penicillin, and 100 
ug/ml streptomycin.  The GL261 cells were cultured in serum-free DMEM/F12 
supplemented with N2, 20 ng/ml mouse epidermal growth factor (EGF, Sigma), 
and 20 ng/ml mouse basic fibroblast growth factor (FGF, Sigma) to expand the 
population of CD133+ stem-like cells. Mouse fibrosarcoma (NCTC 2472) cells 
were cultured in NCTC135 medium (Sigma) supplemented with 10% EVs- free 
serum.  In all experiments, cells were maintained at 37°C in a humidified 
incubator at 5% CO2.  
Primary cultures of murine glia, fibroblasts, melanocytes, and osteoblasts 
were created using previously described protocols and served as non-malignant 
controls for each corresponding tumor cell line. Glia cells were isolated from the 
brain of 1-3 day old neonatal mice21.  The resulting cell suspension was cultured 
in complete DMEM/F12 medium (Lonza) supplemented with 10% EVs-free fetal 
bovine serum (FBS, Gibco), 100 U/ml penicillin, and 100 ug/ml streptomycin and 
seeded in poly-D-lysine-coated tissue culture flasks (Sigma Aldrich). The medium 
was replaced every 3 days and cells were ready for use for experiments after 
removal of the microglia at 14 days of incubation.  The glia cells in culture are 
<90% astrocytes (GFAP positive by florescence microscopy).  Melanocytes were 
harvested from the dorsolateral skin of 1-3 day old neonates141.  Epidermal and 
dermal layers were separated by incubating with 0.25% trypsin for 1 hour at 
37oC.  Single cells were obtained by forcing the digested tissues through a cell 
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strainer and the cells were suspended in melanocyte growth medium (Sigma 
Aldrich) containing 5% FBS.  FBS was excluded from the medium after the first 
two days to allow cell selection for the next 14 days.  Cells were then cultured in 
medium supplemented with 5% EVs-free FBS and antibiotics (purity based on 
anti- melanocyte antibody).  Osteoblasts were isolated from the calvarium of 5-6 
day old neonatal mice141.  Each calvarium was removed from the surrounding 
soft tissue, washed in PBS, and digested in trypsin-EDTA (0.05%) and type II 
collagenase (0.3 Wünsch units/ml).  The mixture was agitated at 37oC and 
150rpm for 15 min. The digestion was repeated 3 more times for 45 minutes 
each.  Cells from the last 2 digestions were collected by centrifugation, passed 
through a strainer, and incubated in complete DMEM (purity based on 
osteocalcin expression).  Embryonic fibroblasts were isolated from mouse 
embryos at day 14142.  Embryos were removed from the placenta and washed 
with PBS. Heads, heart, and liver were removed.  The rest of the embryo was 
minced in a 0.25% trypsin EDTA solution with a scalpel blade and then pipetted 
up and down for several times. A trypsin EDTA (0.05%)-DNase I (100 Kunitz 
units) solution was added and incubated at 37°C for 15 minutes with occasional 
mixing.  The activity of trypsin was deactivated by adding 1 volume of complete 
DMEM.  Cells were then centrifuged, and cell pellet were resuspended in 
complete DMEM, passed through a cell strainer, and seeded in a gelatin coated 
flask.  Pure cultures of embryonic fibroblasts were achieved after the third 
passage (purity based on anti-fibroblast staining).  
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Bone marrow derived monocytes (BDMCs) were isolated from femurs and 
tibia of adult mice.  Briefly, both ends of femurs and tibias were incised to allow 
bone marrow cells to be flushed out by balanced salt solution (BSS) using a 
syringe with 27-gauge needle. Cells were washed with BSS twice, resuspended, 
and passed through a cell strainer.  Bone marrow cells (14× 106 cells per T75 
flask) were cultured in complete DMEM with 3ng/ml of recombinant granulocyte-
macrophage colony-stimulating factor (GM-CSF) (R&D System) to promote the 
maturation of monocytes (based on CD11b+CD11C- cells).  On day 4 of 
incubation, cultures were re-stimulated with GMCSF and were used for the 
addition of EVs. 
EVs isolation and analysis  
Supernatants from tumor and control cells were collected every 24 hrs.  
Supernatants were centrifuged twice at 4,200xg for 30 minutes to remove cell 
debris.  Total EVs isolation reagent (Invitrogen) was added to the debris-free 
supernatant and EVs isolated according to the manufacture protocol.  The size of 
EVs which ranged from 80-150nm was confirmed by NanoSight analysis.  EVs 
were analyzed by flow cytometry for surface protein expression, CD63.  Briefly, 
EVs were incubated with aldehyde/sulfate latex beads (Invitrogen) per the 
manufacturer protocol.  The EVs were then incubated with fluorescently labeled 
antibodies for CD63.  The EVs were washed and analyzed on LSRII (BD).  
Isolated EVs were also analyzed for CD63 by western blot (BioRad) following 
lysis using Total EVs RNA and protein isolation kit (Life Sciences).  To determine 
concentration of EVs, Bradford assay was performed.  Florescent imaging of EVs 
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was conducted by labeling EVs with carboxyfluorescein succinimidyl ester (2μM) 
(Thermo Fisher Scientific) and added to 50,000 monocytes grown on coverslips.  
After 2 hours, monocytes were washed and fixed with 4% paraformaldehyde.  
Monocytes were then incubated with biotin-conjugated rat anti-mouse CD11b 
antibody (BD Biosciences) followed by prediluted streptavidin-HRP solution (BD 
Biosciences).  Signal was amplified by TSA Plus Cyanine 3 system (Perkin 
Elmer).  Cells were visualized using the Zeiss LSM 700 confocal microscope. 
Real-time PCR 
EVs were isolated as described above and added to bone marrow derived 
monocyte cultures for 3 consecutive days (100μg to 1x106 monocytes).  On day 
4, EVs-treated monocytes were washed twice with PBS, scraped, and lysed for 
RNA isolation using SV Total RNA Isolation Kit (Promega).  First strand cDNA 
was generated from 1μg of total RNA using oligo(dT)12–18 primers and 
Transcriptor First Strand cDNA Synthesis Kit (Clontech).  Real time PCR 
reactions were conducted with FastStart SYBR Green Master Mix (Qiagen Rotor-
Gene Q). Briefly, 0.5μM primers, 1X SYBR Green Master Mix, and 2μl diluted 
cDNA were combined.  The primers sequences were previously published, IL-10, 
IL-12, TNFα, TGFβ, iNOS, arginase I, and SOCS321, 143.  Real time PCR was 
conducted on a Qiagen-Q using a hot start with cycle conditions, 40 cycles; 95°C 
15 seconds, 60°C 10 seconds, and 72°C 15 seconds; followed by a melt from 
75°C to 95°C.  Quantitation of the mRNA was based on standard curves derived 
from cDNA standards for each primer set that are run with the samples.  
Samples were normalized based on β-actin expression.  All samples were run in 
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triplicate.  Statistical analysis comparison between groups was determined by 
one-way ANOVA and Bonferroni’s multiple comparison test (p<0.001).   
Flow Cytometry on bone marrow derived monocytes 
EVs were isolated as described above and added to the bone marrow 
derived monocytes for 4 days.  After 4 days, the monocytes were removed from 
culture, washed with FACS buffer, and blocked with antibody to CD16/32 (BD 
Bioscience).  The cells were then incubated with fluorescently labeled antibodies 
specific for CD11b and Ly6C, CD80, PD-L1, or MHC class II.  Monocytes were 
analyzed by flow cytometry on LSRII (BD) gating on live cells and CD11b+ cells.  
T cell proliferation and cytokine assays 
Mice were primed with Theiler’s murine encephalomyelitis virus (TMEV) 
capsid epitope VP421-40 in complete Freund’s adjuvants emulsion containing 
respective peptide and Mycobacterium tuberculosis H37Ra (Difco Laboratories).  
Seven days later, spleens were removed from mice and dissociated to obtain a 
homogenous cell suspension.  The red blood cells were lysed with ammonium 
chloride solution, and CD4+ T cells were sorted with magnetic beads.  The CD4+ 
T cells were labeled with 4μM CFSE and 5x105 cells were placed in each well of 
a 96-well plate.  Next, monocytes treated with EVs were prepared as described 
above and were added to CD4+ T cells in the plate at 1:5 ratio.  The controls 
consist of monocytes from cultures not treated with EVs or no monocytes added 
to the CD4+ T cells.  The cultures were stimulated with or without specific 
peptides VP421-40.   After 4 days of incubation, CD4+ T cells were removed and 
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analyzed by flow cytometry to determine proliferation based on CFSE staining.  
CFSE staining was gated on CD4+ T cells and live cells.  The supernatant from 



















Significance and future directions 
MS is a chronic demyelinating disease with unknown etiology and 
unpredictable clinical course that predominantly affect women and young adults1, 
2. MS is categorized as immune-mediated demyelinating disease as innate 
immune cells and autoreactive myelin-specific CD4+T cells cause bystander 
damage to the myelin sheet. In MS patients, microglia have been consistently 
found in the lesions, independent of the disease stages23. These CNS-resident 
innate immune cells are found to be activated and have been linked to both 
demyelination and remyelination due to their phenotypical and functional 
plasticity144.Viral infection(s) as the trigger for microglia activation has been 
comprehensively postulated8, 9, 13, 145-147.  Although specific viruses associated 
with the disease has not been determined, the use of antiviral molecule, IFNβ, is 
widely accepted as a beneficial disease management for MS80. As the target is 
unspecified, current therapeutic interventions are only meant to alleviate 
symptoms, slow down progression, but unable to provide a cure. 
TMEV-IDD serves as a tool to investigate the viral etiology of human MS 
as well as the role of microglia in the disease pathogenesis. TMEV is a virus that 
infects the CNS and establishes a persistent infection in the microglia. The 
microglia become activated during TMEV infection to secrete inflammatory 
cytokines and effector molecules which promote neuroinflammation.  Persistent 
TMEV infection leads to the development of a demyelinating disease in mice that 
 122 
is similar to human MS. These studies reveal that microglia secrete exosomes 
during the acute TMEV infection and chronic TMEV-IDD phases. These results 
suggest that a novel mechanism in which exosomes secreted by microglia may 
play a role in maintaining viral persistence and chronic inflammation in the CNS. 
Following TMEV infection in SJL mice, the viral loads are high during the 
first few days in the brain but quickly dissipate to the spinal cord and stay at a low 
level throughout the lifetime of the animal26.  Although TMEV persists in 
microglia, infected microglia produce low levels of infectious viral particles, which 
does not correlate with the high viral RNA/genome loads detected in the CNS72. 
Exosomes are nano-sized vesicles which contain a wide range of cellular 
components released from one cell to be taken up by another to facilitate 
communication. We found that exosomes secreted by microglia in both brains 
and spinal cord of TMEV-infected mice at 2 days and as late as 63 days contain 
viral RNA. Importantly, the viral particles and viral proteins were not present in 
exosomes. These exosomes were taken up and transferred to uninfected CNS 
resident cells (microglia, astrocytes, and neurons) and infiltrating cells (dendritic 
cells, monocytes, and macrophages). Moreover, the viral RNA was present in the 
cells that took up these exosomes and was shown to replicate. These findings do 
not only agree with the previous published literature, and also propose that 
exosomes may be one of the strategies that TMEV viral RNA can be transported 
between cells independent of viral particles and promote persistent infection in 
the CNS.  
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The innate immune response, particularly secretion of type I IFNs, induced 
by TMEV infection has been shown to be essential in the development of TMEV-
IDD41. The expression of innate immune cytokines and chemokines is the 
predominant driver of neuroinflammation present in both acute and chronic 
stages of TMEV infection32. Type I IFNs, cytokines, and chemokines are induced 
in TMEV-IDD via the recognition of viral RNA by innate immune receptors, such 
as TLR3, TLR7, and MDA5, leading to NF-kB activation. In these studies, 
exosomes secreted by microglia during the acute TMEV infection or chronic 
demyelinating disease could activate the expression of type 1 IFNs, IFNα and 
IFNβ, pro-inflammatory cytokines, IL-6, IL-12, and TNFα, and chemokines, 
CCL2, in the uninfected bystander cells. This activation was induced by the viral 
RNA inside exosomes as shown by innate receptor silencing experiments. When 
MyD88 (activated by TLR7), or MAVS (activated by MDA5) were silenced with 
siRNAs, the expression of type I IFNs and cytokines were greatly decreased. The 
rest of the immune response could be triggered by other cellular materials inside 
the exosomes such as miRNA, mRNA, and proteins, which was not the scope of 
this work. These data suggest that the innate immune response can be activated 
in uninfected bystander cells at all phases of TMEV infection by exosomes 
secreted from microglia.  
CNS inflammation induced by innate immune response is associated with 
the development of TMEV-IDD and several neurological diseases including MS. 
These studies showed that exosomes released by microglia isolated from both 
brains and spinal cords at the acute TMEV infection or during chronic 
 124 
demyelinating disease were able to promote inflammation in the CNS of naïve 
mice. Thus, microglia exosomes may also be important in driving inflammation in 
human MS. TMEV-IDD is a useful mouse model to study human chronic 
progressive MS. The knowledge from this model may provide additional insight 
into better understanding the pathophysiology of MS.  
Future studies may further explore the ability of exosomes to 
communicate with peripheral immune cells to mount an immune response and 
promote CNS infiltration of those cells. Additionally, future studies can investigate 
the proteins and the miRNA profile of exosomes secreted by microglia during the 
chronic TMEV-IDD in comparison to other phases using mass spectrometry and 
RNA sequencing, respectively. Exosomes secreted during this phase may 
contain suppressive or activation markers and miRNA that can affect the immune 
response of infiltrating immune cells such as virus-specific CD4+T cells and 
myelin-specific CD4+T. Since these works focused on how exosomes secreted 
by microglia containing viral RNA is involved in the inflammation, contributing to 
TMEV-IDD, the integrity of viral RNA remains to be investigated. Future studies 
could look into how the viral RNA inside of exosomes replicate in the recipient 
cells and whether viral proteins could be synthesized inside the recipient cells.  
Besides studying the role of EVs in neurological diseases, the role of EVs 
in tumor microenvironment was also investigated in this thesis work. During 
pathologic conditions like cancers, tumor cells increase their EVs production 
containing miRNA, mRNA, and proteins that may mediate the immune cell 
response, contributing to the immunosuppressive microenvironment. Monocytes 
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are among the first cells to infiltrate the tumor microenvironment.  The conversion 
of monocytes to suppressor cells is crucial in evasion of the immune response 
and tumor maintenance. The recent studies showed that EVs secreted by a wide 
range of tumor cells including osteosarcoma, glioma, colon carcinoma, sarcoma, 
and melanoma, could be taken up by bone marrow-derived monocytes.  Further, 
the monocytes that took up the EVs secreted by tumors matured toward an 
immune-suppressive phenotype by upregulating the expression of suppressive 
cytokine (IL-10 and TGFβ) and effector molecules (arginase and iNOS).  The 
monocytes also down regulated MHC class II and costimulatory molecules, 
CD80, while increasing the expression of PD-L1 and Ly6C on their surface after 
taking up EVs from tumor cells.  Most importantly, monocytes exposed to EVs 
secreted by tumor cells suppressed activated antigen- specific CD4+ T cells.  
These results demonstrate the important role of tumor derived EVs in promoting 
suppressive tumor environment by acting on immune cells such as monocytes.  
Future studies can further explore the content of these tumor derived EVs and 
their mechanisms of suppression. From a translational perspective, 
EVs/exosomes may advance prognostic and treatment approaches in cancers, 






Figure 31. Exosomes secreted by microglia contribute to the TMEV-IDD 
pathogenesis.  
TMEV infection in susceptible mice leads to a persistent infection of microglia in 
the CNS. TMEV-infected microglia secrete type I IFNs, pro-inflammatory 
cytokines, and chemokines associated inflammation. TMEV-infected microglia 
also secrete exosomes containing viral RNA that can be taken up by uninfected 
bystander CNS cells (microglia, astrocytes, and neurons) and infiltrating immune 
cells (dendritic cells, monocytes, and macrophages). The viral RNA inside the 
microglia exosomes can be transferred to uninfected bystander cells and activate 
an innate immune response in the cells, contributing to the inflammatory milieu in 
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